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ABSTRACT OF DISSERTATION
Identification and Characterization of an Interferon Stimulated Gene That Restricts Alphavirus
Infection and Pathogenesis
By
Subhajit Poddar
Doctor of Philosophy in Biology and Biomedical Sciences
(Immunology)
Washington University in St. Louis, 2017
Professor Michael Diamond, Chair

Viral infection of host cells induces the Type I interferon (IFN) response, which is
characterized by the production of hundreds of IFN-stimulated genes (ISGs). Altogether, these
ISGs function to induce an antiviral state, hindering or blocking various steps of the viral
lifecycle. Many individual ISGs have potent and broad antiviral functions. However elimination
of a single ISG does not completely abrogate protection, suggesting that other ISGs, although
moderate or moderate when considered alone, must work cooperatively to provide optimal
antiviral activity.
In order to identify and characterize novel ISGs, an attenuated strain of the alphavirus
chikungunya (CHIKV-181/25) was tested against an shRNA library of 243 curated murine genes
upregulated during IFN treatment. An attenuated CHIKV strain was used with the assumption
that ISGs with moderate or low activity may be more easily identified due to the reduced
pathogenicity of the virus. In addition, the orthobunyavirus LaCrosse (LACV) was also tested, as
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there have been no large scale ISG screens using this pathogen. A total of 21 and 30 novel
murine ISGs that putatively restrict infection were identified from the CHIKV-181/25 screen and
the LACV screen, respectively.
Although independent confirmation of many candidate antiviral ISG targets using bulk
CRISPR lines is still ongoing, we were able to validate and characterize the antiviral role of one
of these targets, IFITM3, against alphaviruses in vitro and in vivo. Alphaviruses, which were
previously thought to be unaffected by this ISG, exhibit reduced replication due to restriction by
Ifitm3 at the endosomal fusion stage of infection. Ifitm3-/- mice infected with CHIKV exhibited
greater swelling of the ipsilateral foot at peak days of pathology. Higher viral titers in the spleen,
serum and ipsilateral foot were seen at 1 day after infection, coinciding with increased cytokines
and chemokines in the ipsilateral foot. Splenic macrophages from Ifitm3-/- mice exhibited greater
levels of viral antigen at 1 day after infection with CHIKV, and cultured bone marrow derived
macrophages lacking Ifitm3 supported enhanced CHIKV replication. To test whether Ifitm3
restricts encephalitic alphaviruses we infected WT and Ifitm3-/- mice with VEEV-TC83-A3G,
and observed increased mortality and viral burden in Ifitm3-/- animals.
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THE INNATE IMMUNE RESPONSE TO VIRAL INFECTION
The innate immune system allows for the rapid identification and response to infection in
an antigen-independent manner. Through pattern recognition receptors (PRRs), host cells can
detect a wide variety of pathogen-associated molecular patterns (PAMPs). PRRs are found on the
surface, in endosomes, and the cytosol of host cells, and are activated by PAMPs unique to
bacteria, fungi, parasites, or viruses. In the case of viral infection, there are several PRRs which
can identify viral or foreign nucleic acids (1). The RIG-I like receptors (RIG-I and MDA-5)
recognize viral single-stranded (ssRNA) and double-stranded RNA (dsRNA) in the cytoplasm,
while cGAS/STING, IFI16 and DAI detect cytosolic DNA (2). Nucleic acids in the endosome
are recognized by the Toll-like receptors TLR3 (ds RNA), TLR7 (ssRNA), and TLR9 (dsDNA)
(3). Upon detection of viral nucleic acids, signaling cascades are initiated to activate the
transcription factors IRF3, IRF7 and NF-kB. These transcription factors induce the production of
pro-inflammatory cytokines and Type I and III Interferons (IFN) (2).

TYPE I, II AND III IFN
Type I IFNs were first described in 1957 (4). They include IFNα (of which there are 12
subtypes), IFNβ, and a series of other poorly defined cytokines such as IFNε, IFNκ and IFNω
(2). Once secreted, IFN functions in an autocrine and paracrine manner, binding to the Type I
Interferon receptor (IFNAR), a heterodimer which is expressed transiently on most host cells.
This initiates a signal cascade through the JAK/STAT pathway, through which STAT1/STAT2
heterodimers bind to IRF9 and form the IFN-stimulated gene factor 3 (ISGF3) complex. ISGF3
binds to promoters containing IFN stimulated response elements (ISREs) (2), activating the
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transcription of hundreds of genes (2). These genes, classified as Interferon Stimulated Genes
(ISGs), function to restrict pathogenesis at the different steps of the viral replication cycle, thus
inducing a rapid and broad antiviral state in both infected and local naïve host cells.
In addition to Type I IFN, Type III IFN (IFNλ1, IFNλ2, IFNλ3 and IFNλ4) can also be
induced via the detection of viral PAMPs (2, 5), and can promote the induction of ISRE activated
ISGs via the IFNλ receptor, albeit not as potently as Type I. However, the expression of the IFNλ
receptor is restricted to epithelial cells and some immune cells, leaving most cells in the host
unresponsive to Type III IFNs (2, 5).
Type II IFN, consisting only of IFNγ, is not transduced via the direct detection of viral
PAMPs, but rather through the detection of the pro-inflammatory cytokine IL-12. Furthermore,
IFNγ is only produced in neutrophils, natural killer cells and T cells. IFNγ signals through the
Type II IFN receptor (IFNGR), initiating the JAK/STAT pathway and inducing the transcription
of pro-inflammatory and apoptotic genes linked to IFNγ activated site (GAS) promoter elements,
some of which are also found in the ISGs induced by Type I IFN (6).

INTERFERON STIMULATED GENES
In cell culture, the number of ISGs produced varies with the dosage, duration, type of
IFN treatment and cell type tested. By microarray analysis, most cells upregulate between 2001000 unique ISGs (7). The most potently inhibitory ISGs identified thus far function against a
broad spectrum of viruses (7). However, antiviral activity is still seen in mice with targeted
deletions of these ISGs (8), suggesting that other ISGs have significant and unique restrictive
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functions. It is believed that most ISGs function as weak to moderate inhibitors, and work in a
concerted manner to restrict infection.
ISGs preventing entry: IFITMs, which were the first family of antiviral ISGs
discovered, appear to prevent the entry via the endocytic pathway of a broad range of viruses,
including influenza A virus (IAV) and flaviviruses (9). TRIM5α binds to the capsid proteins of
retroviruses and accelerates uncoating of the virion (10). Mx is another potent ISG with antiviral
properties against orthomyxoviruses, bunyaviruses, togaviruses and rhabdoviruses (2, 11). Mx
proteins recognize and sequester viral nucleocapsids, preventing their transport to sites of
genome amplification or egress. ADAP2 has recently been shown to restrict entry of DENV and
VSV by altering endosomal uptake and intracellular trafficking (12).
ISGs preventing viral translation and transcription: Upon recognition of viral dsRNA
in the cytosol, 2'-5' oligoadenylate synthetase (OAS) activates RNAseL to initiate nucleic acid
degradation (13). APOBECs and ADAR have been shown to directly edit viral RNA, resulting in
nucleic acid destabilization and the introduction of lethal mutations. IFITs can block translation
of viral RNA by binding to the eIF3 complex. They can also recognize the 5’-ppp motif on viral
RNA, or the lack of the 2’-O methylation group normally found in eukaryotic RNA, and
prevents translation by directly sequestering them (14). PKR is a prominent ISG, which
functions by binding to viral RNA and blocking translation by phosphorylating (and inactivating)
the translation initiation factor EIF2α (13).
ISGs preventing viral protein function, assembly and egress: ISG15 is an ubiquitin
like modifier that conjugates viral proteins in a process called ISGylation, thus affecting a
plethora of viral protein functions (15–17). Viperin associates with endoplasmic reticulum,

	
  

	
   4	
  

interfering with the assembly of viral proteins and egress of virions at the plasma membrane
(18). Finally, tetherin has been shown to prevent the release of viral particles from the plasma
membrane (19).
Proviral ISGs: ISGs have also been identified that induce an immunomodulatory
response. In a high throughput screen, where ISGs were ectopically expressed in vitro, the ISGs
ADAR, APOBEC3A, LY6E, MCOLN, IDO1, and FAM46C, increased replication of YFV, WNV,
VEEV and CHIKV, though specific mechanisms are as of yet unclear (20). ASCC3 was
identified as a proviral ISG in WNV infection, which dampens Type I IFN dependent signals,
possibly through modulating IRF3 and IRF7 (21). Suppressor of cytokine signaling (SOCS) is
produced early in the Type I IFN response and binds to the phosphorylated tyrosine residues of
the IFN receptors or the JAK proteins, thus blocking JAK-STAT signaling (2). USP18 is a
potent down-regulator of the Type I IFN response. It binds to the intracellular domain of
IFNAR2, altering its conformation and dramatically reducing the binding affinity of IFNα to the
receptor (22).

PRIOR SCREENS TO IDENTIFY AND CHARACTERIZE NOVEL ISGS
The antiviral functions of many ISGs are largely unknown. Small-scale studies identified
a few key ISGs involved in the restriction of certain viruses. For example, an siRNA screen
against influenza A identified IFITM3 as a potent antiviral ISG, and was subsequently confirmed
to restrict WNV and dengue virus (9). The first large scale ectopic expression screen was
published in 2011. In this study, a lentiviral library expressing 380 human ISGs was used to
determine restriction of six different viruses (Hepatitis C Virus (HCV), Human
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Immunodeficiency Virus (HIV), YFV, WNV, VEEV, and CHIKV) (20). This ectopic expression
based analysis identified ISGs that act broadly, or to only one virus. Most ISGs identified had
moderate antiviral activity, and acted as inhibitors of translation. Expression of two different
ISGs led to greater restriction of virus replication (20), confirming the notion that IFN based
protection requires the additive effect of multiple ISGs.
Another group developed a large-scale screen to identify novel ISGs against WNV (21)
by silencing gene targets using a lentiviral shRNA library against 245 human ISGs (23). This
allowed investigation of the physiological role of each ISG in the context of an IFN-induced
antiviral state. This approach could potentially identify ISGs that required a multicomponent
complex to function. The screen against WNV identified 30 ISGs, of which 9 had not been
previously identified to have any antiviral effect.
Other groups have performed genome wide siRNA based screens to identify novel ISGs
in vitro against VSV, MHV-68, and HCV (24–26). An in vivo RNA interference screen was
developed in which mice were infected with a library of Sindbis viruses (SINV) encoding
artificial microRNA (amiRNAs) against murine ORFs. Virions with amiRNAs targeting
inhibitory genes were selected for, and the transcription factors like Zfx and Mga were identified
(27).
Recently a library of human and macaque ISGs were screened against eleven different
retroviruses (28). Of the top antiviral ISGs discovered, around 60% targeted against a single
retrovirus, while the remaining 40% were broadly effective. In addition, they also uncovered
ISGs that functioned in a species specific manner. For example, human but not macaque
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ANGTPL1 inhibited SIV infection. They go on to show that IDO1 (which was identified in a
previous screen as proviral for other viruses (20)) and TRIM56 inhibit retroviral replication. 	
  

ALPHAVIRUSES
Alphaviruses are enveloped positive-sense ssRNA mosquito-borne viruses of the
Togaviridae family and can be grouped as arthritogenic or encephalitic based on clinical
symptoms. Arthritogenic alphaviruses present with severe polyarthralgia and polyarthritis while
the encephalitic alphaviruses produce a severe febrile illness associated with infection and injury
to neurons, encephalitis, long-term debilitating neurological sequelae, and death. Arthritogenic
alphaviruses include CHIKV, Sindbis virus, O’Nyong-nyong virus, Ross River virus, Mayaro
virus, and Semliki Forest virus and the encephalitic alphaviruses, including Venezuelan (VEEV),
Eastern, and Western equine encephalitis viruses.

CHIKUNGUNYA VIRUS
CHIKV was originally isolated in 1952 in Tanzania, and has since cause explosive
outbreaks worldwide. In fact, its name was derived from the Makonde word meaning “that which
bends up”, alluding to the changes in posture and joint inflammation of patients suffering from
the arthritic symptoms of infection (29).
Typically, patients infected with CHIKV develop a severe febrile illness marked by
polyarthritis, headache, conjunctivitis, and rash that can progress to persistent arthritis that can
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last for years after infection. CHIKV has become a growing concern since it emerged in the
Caribbean in 2013 and subsequent spread to Central, South and North America, resulting in over
1.8 million cases (30). Currently, there are no approved therapies or vaccines to combat or
prevent CHIKV infection.
CHIKV enters host cells via clatherin-mediated endocytosis, and fuses with the
endosome in a pH-dependent manner. Replication of genomic RNA and translation of capsid
protein occurs in the cytoplasm, which assemble into nucleocapsid cores. The E1 and E2
glycoproteins are translated in the endoplasmic reticulum, and further processed in the Golgi,
before going to the plasma membrane. Nucleocapsid cores assemble with the surface
glycoproteins at the plasma membrane, leading to budding of mature virions (31).
There are two mouse models of infection, the neonate model which can be used to
determine viral dissemination and lethality, and the adult model which is used to better
understand the acute symptoms and persistence of CHIKV-induced arthritis (32–34). In wild
type mice as young as 4 weeks old, a biphasic pattern of swelling is observed in the inoculated
foot. The first, small peak of swelling is seen at day 2 or 3 post infection, and is believed to be
the result of viral replication in the fibroblasts, myocytes and osteoblasts, causing cell death,
cytokine production and edema. The second, more prominent peak of swelling occurs at day 6-7
post infection, which is largely due to infiltration of immune cells and the subsequent induction
of edema, myositis and synovitis. Swelling rapidly drops to near normal levels soon after.
Infectious CHIKV can be isolated from the serum, spleen, muscles, liver and ankle joints as early
as 1 day post infection, but is rapidly cleared and typically undetectable by 5 to 7 days post
infection. However, CHIKV RNA can be detected in the spleen for up to 42 days post infection,
and in the joints for essentially the life of the animal (35–37). In addition, studies have shown
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that osteoblast infection induces increased osteoclast production in the joints, resulting in
possible bone loss (38, 39).
CHIKV-181/25 (TSI-GSD-218) is an attenuated strain developed by the US Army
through 18 serial passages of the parental CHIKV 15561 strain (40). While CHIKV-181/25 is
immunogenic and protective, 8% of recipients developed chronic joint inflammation (41), and in
at least one case symptoms were linked to a genetic reversion of the virus, thus preventing its use
as an effective vaccine. The attenuated phenotype is mapped to two mutations in the E2 protein,
which disturbs the binding of the virion to heparan sulfate on the cell surface. This reduction in
binding affinity reduces the efficiency of infection, and also in turn affects cell spread and
tropism in vivo (42). CHIKV-181/25 does not cause weight loss or death in WT, or in IFNγR-/mice, and reduced morbidity in IFNAR-/- mice. Stat1-/- mice and IFNαβγ receptor knockout mice
both suffer significant weight loss and mortality. Combined with evidence that IFNAR+/- mice
have reduced morbidity than IFNAR-/- mice, it can be inferred that CHIKV-181/25 is susceptible
to Type II and Type I IFN responses (43, 44).

IDENTIFIED ISGS AGAINST ALPHAVIRUSES
There are several studies characterizing the effect of ISGs against alphavirus infection.
ISG15 protects against SINV in vivo, likely via conjugation (ISGylation) to viral proteins (15–
17). Zinc finger antiviral protein (ZAP) restricts SINV, Ross River, Semliki Forest, and VEEV
by blocking the accumulation of viral genomic content in the cytoplasm (8). Tetherin has
recently been shown to prevent egress by tethering virus onto the cell membrane (19), and ZAP
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has been shown to work synergistically with 16 other ISGs to enhance restriction, including
IFITM3 (45).
In the absence of IFN, SINV is poorly restricted by RNaseL, and strongly inhibited by
PKR in the context of replication in DCs (46). However, PKR-/- mice are still protected from
lethal infection of SINV (8), suggesting that other ISGs can still confer protection. A genetic
screen of SINV infected PKR/RNaseL double knockout mice revealed 44 unique ISGs with
possible antiviral activity, including Isg20, Ifit1, Ifit2, Ifit3, and viperin (also shown to be
restrictive against CHIKV) (47). However, in the case of Ifit1, which recognizes RNA lacking a
2’O-methylation on the 5’cap structure and prevents translation, alphaviruses subvert this
antiviral function via RNA secondary structure motifs that inhibit binding (48). Other ISGs like
HSPE and P2RY6 have been identified, though their mechanisms of restriction are currently
unknown (7, 20).

LACROSSE VIRUS
LaCrosse (LACV) is an enveloped negative-sense ssRNA orthobunyavirus with a
segmented genome. This arthropod-borne virus is endemic to the United States (27, 28), and
typically causes disease in children. While most cases are asymptomatic or manifest in febrile
illness, a small percentage of children develop seizures, chronic epilepsy, or fatal encephalitis
(29).
The replication cycle of bunyaviruses begins upon entry into host cells by clathrinmediated endocytosis. After pH-dependent fusion with the endosomal membrane and entry into
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the cytosol, the encapsidated viral RNA genome segments undergo transcription by viral RNA
dependent RNA polymerase (RdRp) to generate mRNA. The mRNA is then used to transcribe
structural and nonstructural viral proteins. Structural proteins Gc and Gn dimerize in the ER and
are transported to the Golgi. Meanwhile, RdRp generates positive strand antigenomic RNA,
which is then used as a template to replicate more genomic copies. Ribonucleoproteins are
generated in viral ‘factories’ and then transported to the Golgi for assembly. Virions are secreted
via vesicles to the plasma membrane (30). LACV and other orthobunyaviruses can antagonize
IFN production responses, particularly through the nonstructural protein NSs, which directly
suppresses IFN induction (31). Mice infected with LACV succumb to neurological disease in a
dose and age-dependent manner. This is believed to be due to differences in Type I IFN
production. Older mice have more myeloid DCs present, which produce more Type I IFN via
RLR and TLR3 activation (32). Selectively removing myeloid DCs from older mice increased
susceptibility to LACV mediated neurological disease (32).
A few well-known, strongly antiviral genes have been reported to restrict Bunyaviridae
family members. Bunyaviruses like LACV and Rift Valley Fever Virus (RVFV) are strongly
restricted by MxA, a highly conserved GTPase that prevents virus components from trafficking
from the cytosol to the nucleus (33). MxA is potent enough to protect IFNAR-/- mice from a
lethal dose of Thogoto virus (tick borne orthobunyavirus) and enhance resistance against LACV
(34). Viperin (blocks egress), MTAP44 (aggregates microtubules; antiviral function unknown)
and PKR (blocks translation) restrict infection by Bunyamwera Virus (35). IFITM2 and IFITM3
were found to restrict RVFV in cell culture, by blocking viral fusion with the endosomal
membrane, while IFITM1 had no discernable effect (36). Recent studies have shown that
Oropouche and LACV are restricted by Irf3, Irf5 and Irf7 in the mouse, where the deletion of all
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three genes leads to increased viral replication in the liver and spleen, and induces early
mortality. Irf5 in particular was found to be required for control of viral replication in bone
marrow derived DCs, faster infiltration of into the CNS and death (49, 50). In addition, both
murine and human IFIT1 was found to have no discernable effect against Oropouche or LACV
in vitro and in vivo (51).

IFITM
The interferon induced transmembrane (IFITM) family of proteins broadly restricts
infection of several families of viruses. These proteins are expressed constitutively in most cell
types, but also can be induced by type I, II and III IFNs (52). IFITMs are classified according to
sequence similarity and function: Clade 1 contains IFITM1, 2 and 3 (and the mouse orthologs 6
and 7), which participate in viral restriction; Clade 2 contains IFITM5, which is expressed in
osteoblasts; and Clade 3 contains IFITM10, which is yet uncharacterized. Only IFITMs in Clade
1 are IFN inducible (14, 52).
Clade 1 IFITMs have 5 conserved domains (9, 52): the N terminal, the intramembrane,
the conserved intracellular loop, the transmembrane, and the C terminal. IFITM2 and 3 contain a
YXXΦ motif allowing for internalization into endosomes (53). IFITM1 lacks this motif and is
believed to associate with the caveolin pathway. Further biochemical studies have identified key
regions that affect IFITM function and localization. Lys124 in the N terminal domain is a site for
ubiquitination (54), which mediates IFITM degradation. Palmitoylated cysteines in the
intermembrane and transmembrane domains are necessary for localization and restriction of viral
entry (54), and methylation of K88 appears to counter IFITMs antiviral capacity (55). The
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orientation of IFITMs is largely unclear, and in the case of IFITM3, there are three prevailing
models. However, the model with the most support has the N terminal domain in the intracellular
region, and the C-terminal domain exposed to the extracellular space.
IFITM proteins are basally expressed and localized primarily in late endosomes and
lysosomes (52), co-localizing partially with LAMP2 and CD63 (56, 57). In addition, IFITM3
associates with lipid rafts on the plasma membrane (58), and is expressed on the apical
membrane and cilia of columnar epithelial cells of the airway (59). IFITM1 appears to colocalize to subcellular compartments separate from IFITM2 and IFITM3 (60, 61). Ectopic
expression of IFITMs results in increased expression on the plasma membrane surface.
Furthermore, IFITM1 ectopic expressing cells have larger, empty vesicles, and IFITM3 cells
develop multivesicular bodies (62).
Antiviral activity of IFITMs was first observed against VSV (52), where infection was
restricted in IFITM1 over-expressing cells. IFITM3 was later found to restrict influenza A by
blocking entry at the hemifusion stage (9) in the late endosome, and also is protective in vivo (59,
63). Since then, the effectiveness of IFITM restriction has been tested in vitro against many
viruses (64). IFITM genes reportedly restrict infection of flaviviruses (WNV, DENV, ZIKV and
JEV), HCV, filoviruses (EBOV and MARV), SARS coronavirus, bunyaviruses (RVFV, LACV),
HIV, RSV and reoviruses (56, 60, 61, 64–71). IFITM3 has been shown to prevent HIV-1
infection by incorporating directly into the virion, as well as preventing viral fusion and cell-tocell spread (72). In addition, HIV-1 has been shown to gain sensitivity to IFITM mediated
restriction as the virus population develops mutations on the envelope glycoprotein to evade host
neutralizing antibodies (73–75).
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IFITMs reportedly do not have significant antiviral activity against Moloney Murine
Leukemia Virus (retrovirus), Crimean–Congo Hemorrhagic Fever (CCHFV, a bunyavirus), and
arenaviruses (9, 14, 20, 56, 60, 65). In addition, IFITMs do not restrict DNA viruses like Human
Papilloma Virus (HPV), and Adenovirus (76), but may restrict Cytomegalovirus (CMV) and
African Swine Fever virus (77). It is currently unknown why these viruses escape IFITM
restriction, especially since many share common characteristics of entry as restricted ones.
Correspondingly, the mechanism of protection by IFITMs also remains unclear. Over-expression
of IFITMs has been shown to reduce membrane fluidity, increase cholesterol content and alter
the curvature of endosomes, suggesting that IFITM physically alters the properties of the
membrane to make viral fusion inefficient (78). For example, Amphotericin B, an antifungal that
binds sterols in membranes, abrogates IFITM3 protection from influenza (79).
The human polymorphism rs-12252 results in the deletion of the 21-nucleotide end of the
N terminal of IFITM3. This deletion prevents localization to the endosome, restoring influenza
(an observation that has been questioned in later publications (80, 81)) but not HIV infection
(82). In addition, a recent publication with Hantaan virus suggests that the rs-12252
polymorphism is responsible for increased disease severity and viral load in patients (83). These
studies introduce the possibility that IFITM has more than one method of restriction.
In this study, we use a library of murine ISG candidates to identify novel antiviral genes
in a high throughput manner. As most ISGs are believed to have a moderate to low potency, we
decided to use an attenuated alphavirus (CHIKV-181/25) to try to identify novel targets that may
be masked in the context of a more pathogenic strain. In addition, the orthobunyavirus LACV
was also used, as this virus has not been previously used in large scale ISG screens. While the
initial results still need to be independently verified, the screen identified the ISG Ifitm3. Though
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Ifitm3 has been characterized as a potent and broad antiviral gene, alphaviruses were considered
to be unaffected. Through in vitro and in vivo studies, we show that both arthritogenic and
encephalitic alphaviruses are susceptible to Ifitm3 mediated restriction.
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Chapter 2: Screening for novel antiviral ISGs against alphaviruses and orthobunyaviruses
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ABSTRACT
The identification and characterization of novel antiviral interferon-stimulated genes
(ISGs) can help elucidate functions of viral replication and pathogenesis in vitro and in vivo. In
addition, identifying novel mechanisms of restriction can provide new avenues of therapeutics
for many viral diseases, including arboviruses like chikungunya and LaCrosse virus. Using a
shRNA library targeting 243 unique ISG candidates, a total of 21 and 30 novel genes were
determined to be antiviral against the attenuated strain CHIKV-181/25 and LACV, respectively.
However, the efficacy of the screen was called into question, as only 1 of every 3 shRNA
constructs against a particular gene was guaranteed to produce significant knockdown, and offtarget effects were never assessed. Independent assessment of the top hits against CHIKV181/25 using a transducible system to generate bulk CRISPR knockout cell lines has proven
ineffective, and would require the generation of clonal lines before proper analysis can be done.
Verification of certain target ISGs through readily available knockout cell lines and mouse
models led us to identify Ifitm3 as having antiviral mechanisms against alphaviruses.
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INTRODUCTION
Of the hundreds to thousands of ISGs that are upregulated upon infection, the functions
of only a small handful have been identified and further studied. An antiviral response is still
seen in cell culture systems with the most potent ISGs removed, suggesting that the remaining
uncharacterized ISGs have some protective functions. Most of these ISGs likely have mild to
moderate antiviral activity on their own, and likely work synergistically to provide stronger
restriction. Other ISGs may only be effective against a particular strain or family of viruses.
Given the sheer number of ISGs, it is also likely that these genes have redundant functions,
acting as a countermeasure against viruses that have evolved a means of avoiding restriction by
other ISGs with a similar, but not exact mechanism of action.
Prior large scale screens for ISGs have focused on human targets (9, 20, 21, 24–26, 28,
84), and used non-attenuated viruses. Although identifying novel antiviral human ISGs could
direct a path toward targeted therapeutics, validation studies in animals would likely still be
required. Some ISGs (like IFI6) identified from human screens against WNV did not have
apparent mouse orthologs in part due to gene duplication and diversification, limiting their
potential for further pathogenesis studies in vivo. Non–attenuated viruses may have the
disadvantage of having mechanisms for antagonizing the function of specific ISGs or the IFN
signaling response in general. In this case, moderate or weakly potent antiviral ISGs might be
masked in a screen. Some attenuated or vaccine strains show impaired virulence due to their
greater sensitivity to IFN, like WNV-Kunjin (85), making them a useful tool to reveal new
antiviral ISGs. Furthermore, ISGs that are effective only against attenuated viruses can suggest
novel viral immune evasion mechanisms. As an example, a virulent strain of WNV commonly
used for pathogenesis studies exhibited no phenotype in IFIT1-/- mice or primary cells; the role of
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IFIT1 as an antiviral effector was revealed with an attenuated genetic mutant virus that lacked
2’-O methylation on its viral RNA (86, 87).
In this study, we employed a library of 756 unique shRNAs (targeting 243 unique murine
ISGs) to screen against the attenuated alphavirus vaccine strain of chikungunya virus CHIKV181/25. In addition, we also used the library against the orthobunyavirus LACV, which has not
been subject to a large, high-throughput ISG screen. As a segmented negative-stranded RNA
virus, La Crosse is a unique encephalitic arbovirus and may thus be restricted by a distinct set of
ISGs. By using a gene knockdown approach, this screen has the additional advantage of
identifying antiviral ISGs in the context of physiological doses of IFN, and can be used to
recognize ISGs that require a multi-component complex to function. From our initial screens, we
identified 21 and 30 novel candidate antiviral ISGs against CHIKV-181/25 and LACV,
respectively. While the results included ISGs of known antiviral function, providing evidence
that the screen was successful, subsequent analysis of individual shRNAs against a particular
gene target suggested that many of our results could be due to off-target effects. Independent
assessment of select targets using bulk CRISPR lines has been so far incomplete, and further
optimization of the system needs to be done.
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MATERIALS AND METHODS
Cells. Vero, 293T, NIH 3T3 cells and MEFs were cultured in complete DMEM, which
was supplemented with 10% fetal bovine serum, and 10 mM each of GlutaMAX, sodium
pyruvate, non-essential amino acids and HEPES (pH 7.3). MEFs from β2mKbDb triple knockout
mice were provided by Ken Murphy (Washington University in St Louis).
Viruses. The CHIKV-181/25 strain was provided by the World Reference Center for
Arboviruses (R. Tesh, University of Texas Medical Branch). The CHIKV-LR (La Reunion
OPY1 p142) strain was a gift from S. Higgs (Kansas State University). LACV (original strain)
was provided by Andrew Pekosz (Johns Hopkins University, Baltimore, MD) Virus propagation
and titration was performed in Vero cells.
Lentiviral packaging and transduction of shRNA. The shRNA library targeting
murine ISGs was purchased commercially (Open Biosystems), and uses the lentiviral pGIPZ
vector. This plasmid co-expresses shRNA and GFP downstream of the CMV promoter.
Individual plasmids from the library were co-transfected in a 96 well format into 293T cells with
the packaging plasmids pSPAX.2 and pMD2G using the FuGENE HD (Roche) transfection
reagent, following manufacturer’s instructions. After 48 hours, lentiviral supernatants were
harvested and transferred onto NIH-3T3 cells in a 96 well format with a final concentration of
10ug/ml polybrene. Cells were spinoculated at 1000 x g at room temperature for 30 minutes
before being placed in the 37°C incubator. Supernatant was replaced with complete DMEM 24
hours later and returned to 37°C for 48 more hours to allow for efficient expression of GFP
reporter and knockdown of the target genes.
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ISG screening. The NIH-3T3 cells transduced with the lentiviral library for 72 hours
were then treated with commercial mouse IFNβ (PBL) (2.5 IU/ml for CHIKV-181/25 or 1 IU/ml
for LACV) for 6 hours, washed, and then infected with virus (MOI 5 of CHIKV-181/25 or MOI
200 of LACV). These MOIs were chosen to facilitate 2-5% infection in the presence of IFN
treatment or 70-80% infection in the absence of IFN treatment. After 14 hours (CHIKV-181/25)
or 48 hours (LACV), cells were trypsinized, fixed in 1% PFA and permeabilized with a 0.1%
saponin solution in HBSS and 10mM HEPES. CHIKV infected cells were stained with CHK11,
a mouse monoclonal antibody specific to the E2 protein, and LACV infected cells were stained
with supernatants from the hybridomas 807:31 and 807:33, kindly provided by Andrew Pekosz.
Following secondary antibody staining with goat-anti mouse IgG-Alexa Fluor 647 (Life
Technologies), cells were analyzed by flow cytometry using the FACSArray Flow Cytometer
(BD Biosciences). Transduced populations were identified by GFP, and infected populations
were identified by Alexa Fluor 647 staining.
Generation of bulk CRISPR lines. Single guide RNAs (sgRNA) were identified using
the online algorithm developed by the lab of Feng Zheng and the Broad Institute
(www.broadinstitute.org/gpp/public/analysis-tools/sgrna-design).

Briefly,

the

algorithm

determined a series of possible guides that could bind to the gene of interest and ranked them
according to predicted specificity and efficacy. The top three ranked guides were chosen, flanked
with the correct nucleotide sequences (Oligo 1: 5’-CACCG; Oligo 2: 5’-C and 3’-AAAC) to
accommodate ligation into the LentiCRISPRv2 vector, and commercially produced (IDT).
Guides are provided in Table 1.
LentiCRISPRv2 (Addgene 52961) is a lentiviral plasmid with Cas9 and the puromycin
resistance gene expressed under the EFS promoter, and a U6 promoter just upstream of a 2kb
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filler region flanked by BsmBI restriction sites. The filler region was removed via BsmBI
digestion and gel purification, and then replaced with sgRNAs via T4 DNA Ligase. The plasmids
were then transformed, collected via Qiagen’s MiniPrep kit, and sequence verified using the
following primer: U6 Fwd 5’-GAGGCCTATTTCCCATATTCC-3’.
The LentiCRISPRv2 library was packaged in 293T cells in 6 well plates with pSPAX2
(Addgene 12260) and pMD2.G (Addgene 12259), using the FuGENE HD (Roche) transfection
reagent. After 48 hours, lentiviral supernatant was removed and collected. Low passage NIH3T3 cells plated in 12 well plates were then spinoculated with lentivirus and 10ug/ml polybrene
for 30 minutes at room temperature at 1000 x g. The next day, cells were split 1:4 and given
fresh complete DMEM with 2µg/ml puromycin to select for transduced cells. After 7 days of
selection, cells were aliquoted and frozen down.
IFN treatment, infection with CHIKV-181/25 and analysis were optimized to provide a
consistent 4-6 fold difference between negative control, scrambled sgRNA, and STAT1 sgRNA
bulk CRISPR lines. At 14 hours post infection, cells were harvested, fixed, stained and analyzed
by flow cytometry as described above.
Western Blotting. Negative control scrambled and Ifitm3 bulk CRISPR lines were lysed
in RIPA and electrophoresed under reducing conditions on a 4-12% Bis-Tris NuPAGE gel with
MES buffer according to the manufacturer’s instructions (Thermo Fisher). After transfer onto
PVDF membranes (Thermo Fisher) using an iBlot apparatus (Thermo Fisher), proteins of
interest were detected with mouse anti-β-actin (CST, 8H10D10), Polyclonal rabbit anti-Ifitm3
(Proteintech, 11714-1-AP), HRP-conjugated anti-mouse IgG (Sigma Chemical), and HRPconjugated anti-rabbit IgG (Sigma Chemical).
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Mice. Lamp3-/- mice were generated by CRISPR, deleting 11 or 335 nucleotide deletions
in exon 2 of the Lamp3 gene, both of which result in a frame shift and a premature stop codon.
Both alleles were backcrossed twice to C57BL/6J mice to remove potential off-target effects and
then generated mouse lines using brother by sister mating. Ifit2-/- mice were made commercially
(Taconic) in the C57BL/6 background, wherein exons 2 and 3 of the Ifit2 gene were flanked by
flt sites and then excised via Flt recombinase. Mice were either infected in the footpad with
CHIKV-LR at a final volume of 10ul, or with LACV with a final volume of 50ul, diluted in PBS.
Viral burden of tissues or serum harvested were done by a focus forming assay.
Viral growth kinetics. For viral yield assays, cells were plated (105 cells per well in a
12-well plate) and in some experiments pretreated with specified doses of IFNβ for 12 hours.
Cells then were infected with CHIKV at 37°C. One hour later, the plates were rinsed twice with
warm PBS, and replaced with fresh DMEM supplemented with 10% FBS. Supernatants were
collected at specific time points, and viral titers were determined by focus forming assay on Vero
cells, as described (37, 48).
Measurement of viral burden by qRT-PCR. Mouse tissue homogenates were
processed for RNA using the Qiagen RNeasy kit. Serum samples were prepared using the
Qiagen QIAmp Viral RNA kit. Viral titers were quantified to a standard curve of CHIKV and
normalized to tissue weight or ml of serum. CHIKV RNA was detected using an E1 specific
primer and probe set.
Data and Statistical analysis. Flow cytometry data was analyzed using FloJo software.
Analysis of the shRNA ISG screen and Z-score calculations were done on Microsoft Excel.
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Student t-tests, Mann-Whitney or Dunnet’s multiple comparison ANOVA tests were performed
with Prism Software (GraphPad, San Diego, CA).
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RESULTS
Screening for novel antiviral ISGs. A library comprised of 756 unique shRNAs,
targeted against 243 putative murine ISGs was obtained commercially from Open Biosystems.
These putative ISGs were identified from a collection of published microarray analyses of genes
upregulated in vitro after treatment with Type I IFN. Each shRNA arrived inserted into the
bicistronic pGIPZ lentiviral vector, which includes a GFP reporter (Fig 2.1A). Individual
plasmids from the library were packaged into lentiviruses and transiently transduced into NIH3T3 cells in a 96 well format. Each plate contained negative scrambled controls and positive
Stat1 shRNA transduced controls. After 72 hours, successful transduction was determined by
GFP expression. Cells were then treated with IFNβ for 6 hours and infected with either CHIKV181/25 (MOI 5) or LACV (MOI 200) (Fig 2.1B). The administration of IFN and virus was
optimized to obtain a low percentage of infectivity in the presence of IFN and a high percentage
in the absence of IFN (3-7% and 70-80% in all transduced cells, respectively) in an attempt to
skew towards the detection of antiviral ISGs. After 14 hours (CHIKV) or 48 hours (LACV), cells
were processed and analyzed by flow cytometry (Fig 2.1C). The transduced (GFP+) cell
population was analyzed to determine the percentage of infected cells (GFP+ Alexa Fluor 647+)
in each well, and subsequently normalized to the percentage calculated in the scrambled controls.
These ratios were then ranked by Z-score. Any shRNA construct with a Z-score of 1.5 (one and a
half standard deviations above the mean) was considered a ‘hit’ in these screens.
In the CHIKV-181/25 screen, a total of 33 shRNAs, corresponding to 28 unique ISG
targets were identified (Fig 2.2A). These included shRNAs targeting the positive control (Stat1)
ISGs with well characterized antiviral function (Stat2 and Ifit1), transcription factors (Irf8), and
proteins involved in antigen presentation (β2m and H2-T). After manually eliminating genes that
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were already characterized, deemed difficult to characterize (such as transcription factors, or
genes canonically involved in the adaptive immune response), a final list of 21 candidate ISGs
was generated. In the LACV screen, a total of 49 shRNAs, corresponding to 46 unique ISG
targets were identified (Fig 2.2B). Like the CHIKV screen, ISGs with known antiviral potency
and mechanism were included. Manual curation of these targets resulted in a final list of 30
unique ISG targets, three of which were also found in the CHIKV screen (Agt, Ifi47, Lypla1). A
table of the final ISGs targets and their known functions are included in Table 2.1.
Independent assessment of the top candidate ISG targets. To better understand the
efficiency of knockdown and potential off-target effects of the library, the Z-scores of all the
shRNAs against the top ISG target hits were directly compared (Fig 2.3). Strikingly, for most of
the gene targets, the majority of the corresponding shRNAs had a Z-score well below 1.5. Even
for the positive control, Stat1, only 3 of the 6 shRNAs had a Z-score greater than 1.5, suggesting
only 50% efficiency of this library at best. Combined with the manufacturer’s claim that “at least
one of three constructs is guaranteed to reduce target mRNA levels by 70% or more,” (Open
Biosystems) the reliability of the shRNA screen is put into question.
To independently verify the top hits, we decided to use the gene editing technology
CRISPR to generate targeted knockout cell lines. We prioritized targets identified in the CHIKV181/25 screen over the LACV screen because there are more reagents available to evaluate
CHIKV pathogenesis. An sgRNA library was first developed using the online designer tool from
the Broad Institute (www.broadinstitute.org/gpp/public/analysis-tools/sgrna-design). The top 3
guides were picked for each ISG target (Table 2.2) and ligated into the LentiCRISPRv2 plasmid
(Fig 2.4), which also expresses Cas9 and the puromycin resistance gene. After packaging, the
CRISPR library was transduced into NIH-3T3 cells and maintained under 2µg/ml of puromycin
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selection for 7 days. After selection, the cell lines were aliquoted and frozen down. Efficacy of
gene editing was tested by treating the scrambled negative control and Stat1 targeted lines with
increasing doses of murine IFNβ for 6 hours and then infecting with different MOIs of CHIKV181/25 for 14 hours. By flow cytometry, all 3 Stat1 bulk CRISPR lines were more susceptible to
infection than scrambled controls, especially as the concentration of IFN was increased (Fig 2.5).
However, analysis of the bulk CRISPR library yielded no clear antiviral phenotype, with only a
few individual lines attaining a 2-fold change increase in infection compared to the scrambled
controls (Fig 2.6). A closer analysis was performed of six ISG targets that had at least one bulk
CRISPR line infected higher than 1-fold. After treating cells with increasing doses of IFN and
virus, only the Ccng1 bulk CRISPR lines had a consistent, increased fold change in infection
compared to scrambled controls. Furthermore, the Ccng1 bulk CRISPR lines showed differences
in infection without IFN treatment, suggesting that the Ccng1 phenotype may not be IFN
dependent (Fig 2.7).
Since the CRISPR screen only validated one gene identified in the shRNA screen, an
additional positive control was included. Even though Stat1 has been used consistently and
successfully for similar ISG screens as a positive control, adding a known, less potent antiviral
ISG could assist in fine tuning the IFN dosage and infection conditions to tease out the effects of
the more moderately acting antiviral genes. The ISG Ifitm3 was chosen, as we had recently
published its antiviral effects on alphaviruses (discussed in Chapter 3 of this dissertation).
Unfortunately, no variation in IFN dosage or MOI tested could induce a satisfactory difference in
infectivity between the Ifitm3 bulk CRISPR lines and the negative controls (Fig 2.8A). By
Western blot, Ifitm3 can still be detected in all three lines, and expression increased if the cells
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were pre-treated with IFNβ (Fig 2.8B). This is likely due to the genetic heterogeneity of the bulk
cells.
Alternative approaches to independently assess target ISGs. Knockout mice were
available for four of the ISGs identified in our shRNA screens. Ifitm3 and Lamp3 were identified
in both the CHIKV and LACV screens, while Ifit2 and β2m were identified in the LACV screen
only. As Ifitm3 had previously been described to restrict orthobunyaviruses in vitro, we decided
to follow up on its potential role in CHIKV instead, using Ifitm3-/- and Ifitm locus deletion MEFs.
Further discussion of these experiments will be in Chapter 3 of this dissertation.
Ifit2 is a potent antiviral ISG that has been shown to restrict viral replication by binding
to subunits eIF3, which is required for initiation and translation (14). In the context of WNV
infection, it was shown that Ifit2 restricts viral replication in the CNS, and only functions in a
subset of primary cells, like cerebellar granule cells and macrophages, but not MEFs (88). The
lack of restriction was also observed in growth kinetics studies with LACV in MEFs (data not
shown). In addition, no significant differences weight in loss and death were observed in 8 to 10
week old Ifit2-/- and WT mice infected with 105 FFU of LACV in the footpad (Fig 2.9).
β2m, or beta-2-microglobulin, is canonically known for its role in stabilizing the structure
of MHCI, which is required for presentation of cellular antigen to CD8+ T cells (89). Due to its
importance in adaptive immunity, studying its potential role as an antiviral ISG in vivo would be
difficult. Instead, β2mKbDb triple knockout MEFs were infected with CHIKV after treatment
with IFN. Interestingly, we noticed that the triple knockout cells were less prone to infection
after 14 hours than MEFs from WT littermate controls (Fig 2.10). Although an interesting
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observation, additional experiments were not performed, and due to the foreseeable difficulty of
properly studying the non-canonical properties of β2m.

Lamp3 is an endosomal-lysosomal associated protein that is highly expressed in the cells
of the airway, and in macrophages and dendritic cells (90), though there has been no extensive
study on its upregulation in other tissues upon IFN stimulation. Recent unpublished observations
have shown that Lamp3 is highly protective against MERS-Coronavirus pathogenesis. One study
in A549 cells suggest that Lamp3 is actually proviral, and is required for the IAV nucleoprotein
and titers (91). In the context of CHIKV infection, no differences were seen after 14 hours by
flow cytometry, nor were any differences seen by growth kinetics (Fig 2.11A-B). When infected
subcutaneously with 104 FFU, WT and Lamp3-/- mice had comparable levels of titer in the
spleen, ankle joints and serum at day 1 and 2 post infection by focus forming assay (Fig 2.12).
To determine if Lamp3 had a possible role in maintaining or clearing the chronic viral RNA seen
in the feet and spleen, infected mice were assayed by qPCR at 21 days post infection. Again, no
differences in viral RNA titer were observed (Fig 2.13). The role of Lamp3 in LACV
pathogenesis has not been studied.
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DISCUSSION
To identify novel antiviral ISGs, a murine shRNA library targeting 243 genes was tested
against the attenuated alphavirus CHIKV-181/25 and the orthobunyavirus LACV. Using
shRNAs to knockdown target genes in vitro allowed for the identification of genes with antiviral
function in the context of physiological response to IFN treatment. In addition, the attenuated
alphavirus and orthobunyavirus were used in an attempt to find antiviral ISGs whose functions
were either likely masked by pathogenic strains, or to identify completely novel, virus specific
gene targets. From the shRNA screen, a total of 28 and 46 unique ISGs were identified that were
deemed antiviral against CHIKV-181/25 and LACV, respectively. These genes included known
antiviral ISGs like Stat 2, Ifit1 and Ifit2, Ifitm3, and Mx1, as well as transcription factors like Irf8
and Irf9. However, a lack of reliability of knockdown by the shRNA library led to a concern that
the unique ISGs in these top hits were the result of off-target effects.
Independent assessment of these targets using bulk CRISPR edited NIH-3T3 cells have
thus far proven to be incomplete, and further optimization is needed before the hits can be
properly analyzed. The current conditions of the CRISPR screen are unable to identify novel
antiviral ISGs less potent than Stat1 or as effective as Ifitm3. Since CRISPR acts by inducing
breaks and random repair of genomic DNA, we cannot guarantee that enough alleles in the bulk
population of cells have been knocked out to see an appreciable change in phenotype. This issue
is compounded by the fact that NIH-3T3 cells are hypertriploid, increasing the likelihood that
some CRISPR targeted cells have at least one functioning target allele. In fact, by Western blot
analysis of the Ifitm3 bulk CRISPR lines, the protein could still be detected, especially in
samples where the cells were stimulated with IFN.
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To salvage the CRISPR screen, we would have to generate and validate (by DNA
sequencing and, if reliable antibodies are available, by protein detection) clonal knockout lines
for each ISG target from the bulk populations. This way, we can cleanly assess the role of each
target ISG without background noise from partially affected or unaltered alleles. Furthermore,
any potential trans functions an ISG may have will no longer be a factor. Positive hits should be
re-assessed on other cell lines (such as MEFs, BV2s, and human lines like HeLas and 293Ts) to
address the possibility that the phenotype observed is unique only to NIH-3T3s.
A better approach for this screen or for future high throughput screens could be to try
CRISPR interference (CRIPSRi), which represses gene expression at the transcriptional level,
physically blocking the progress of RNA polymerase. Using this knockdown method, which can
be stably transduced, heterogeneity of mutations at the genomic level can be avoided while we
can take advantage of the specificity of the sgRNA-dCas9 system. Validation can be done by
RT-PCR (presence or lack of mRNA) and by Western blot. One caveat is that the efficiency of
knockdown decreases the further the target is from the transcription start site, which may limit
the number of possible sgRNA candidates per gene.
Another option would be to step away from the CRISPR lines and see if ectopic
expression of the ISG targets yields any results. This approach is beneficial because we can
theoretically track the cells that have incorporated the expression vector by flow cytometry, and
determine the antiviral potency of each target ISG in the absence of IFN stimulation. However,
this runs contrary to the spirit of the original screen, which was designed to understand a target
ISGs importance in a physiological antiviral environment.
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In summary, we attempted to identify novel antiviral ISGs in a high-throughput manner
using a gene knockdown system and viruses that are either attenuated or not previously tested in
prior, similar studies. This shRNA based screen identified a series of novel and previously
described ISG targets. Due to the unreliability of the knockdown system, the validity of these
hits is questionable at best. However, by using available knockout reagents for a select number
of the top ISGs, Ifitm3 was found to restrict CHIKV infection.
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Figure 2.1
A

B

C

Figure 2.1. Lentiviral based shRNA screen for ISGs that restrict alphavirus or
orthobunyavirus infection. (A) Plasmid map of the pGIPZ plasmid containing the shRNA oligo
and the IRES GFP reporter. (B) The shRNA library targeting ISGs were packaged and
transduced into NIH-3T3 cells. 72 hours later, cells were treated with IFNβ (2.5 IU/ml for
CHIKV and 1 IU/ml for LACV) for 6 hours then infected with CHIKV-181/25 or LACV at MOI
5 or MOI 200, respectively. After 14 hours (CHIKV) or 48 hours (LACV), cells were processed
for flow cytometry. (C) Representative flow plots of non-silencing control (NSC) transduced
cells or Stat1 shRNA transduced control cells infected with CHIKV-181/25. Transduction
efficiency is determined by the expression of GFP on the x-axis and infection efficiency is
shown by viral envelope staining on the y-axis.
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Figure 2.2
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Figure 2.2. Analysis of the ISG screen. After flow cytometry, the percentage of infected cells
of the total transduced population for every well was normalized to that of the non-silencing
control. This ratio was normalized by Z-score and ranked for (A) CHIKV-181/25 and for (B)
LACV. The top hits with a Z-score of 1.5 and above are listed on the table to the right. Each dot
represents a single shRNA in the library.
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Figure 2.3

	
  

	
  37	
  

Figure 2.3. Efficacy of the shRNA library. The Z-scores of all the shRNAs targeting the top
ranked ISGs from the CHIKV (top) and the LACV (bottom) screens were directly compared.
Dotted lines mark Z-score at 1 and 1.5 for the CHIKV graph, and 0, 1, 1.5 and 2 for the LACV
graph. Dashed lines represent the the median value. Z-score threshold for both screens was 1.5
(1.5 standard deviations above the mean).
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Figure 2.4

Figure 2.4. CRISPR knockout of select ISGs. Plasmid map of the LentiCRIPSRv2 vector,
which contains a 2kb filler space under the U6 promoter. This spacer is replaced by the sgRNA
oligo. The Cas9 and puromycin resistance gene cassette are under the EFS promoter.
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Figure 2.5
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Figure 2.5. Demonstration of the efficacy of the CRISPR gene editing system. Non-silencing
control lines and Stat1 bulk CRISPR lines were pretreated with the indicated concentration of
IFNβ for 6 hours before being infected for 14 hours with CHIKV 181/25 at an MOI of 0.5, 1 or
5. Percentages of infection were then determined by flow cytometry. The numbers above
indicate the average fold-difference in infection between the control and the Stat1 bulk CRISPR
lines.
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Figure 2.6

Figure 2.6. Attempt at validating the antiviral phenotype of select ISGs using bulk CRISPR
lines. NIH-3T3 bulk CRISPR lines were treated with IFNβ (3 IU/ml) for 6 hours, then infected
with CHIKV 181/25 at MOI 1 for 14 hours. Cells were then analyzed by flow cytometry. Folddifferences in infection versus control lines are shown here. The dotted line indicates a one-fold
change.
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Figure 2.7

Figure 2.7. Analysis of select bulk CRISPR lines. The bulk CRISPR lines of six ISG targets
from the initial screen were further tested to verify the presence of an antiviral phenotype. Cell
lines were pretreated at the indicated concentrations of IFNβ for 6 hours before being infected
with MOI 1 of CHIKV 181/25 for 14 hours. Cells were analyzed by flow cytometry and the fold
differences in infection compared to controls are graphed. The dotted line indicates a one-fold
difference.
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Figure 2.8
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Figure 2.8. Attempt at showing an antiviral phenotype with Ifitm3 bulk CRISPR lines. (A)
NIH-3T3 bulk CRISPR lines were treated with the indicated dose of IFNβ for 6 hours and then
infected with various MOIs of CHIKV 181/25 for 14 hours before being analyzed by flow
cytometry. (B) Western blot of control and Ifitm3 bulk CRISPR lines with or without 3 IU/ml
IFNβ treatment for 6 hours.
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Figure 2.9

Figure 2.9. Pathology of LACV in Ifit2-/- mice. 8 week old WT and Ifit2-/- mice were infected
with 105 FFU into the footpad and followed for weight loss. No mortality was seen during the
course of infection.
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Figure 2.10

Figure 2.10. Susceptibility of β2mKbDb triple knockout MEFs to infection by CHIKV
181/25. MEFs were treated with the indicated concentration of IFNβ for 6 hours before being
infected with various MOIs of CHIKV 181/25 for 14 hours. Cells were analyzed by flow
cytometry. Means were compared by Student t-test. (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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Figure 2.11
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Figure 2.11. CHIKV infection is not enhanced by Lamp3 in vitro. WT and Lamp3-/- MEFs
were treated with IFNβ and then infected with either (A) MOI 0.1 or (B) MOI 5 of CHIKV
181/25. Virus Statistically significant but inconsequential differences were observed in the
multistep growth kinetics (A) of CHIKV in the absence of IFN, as well as in percent infection of
MEFs at low dose of IFN. No differences were seen in viral growth kinetics at (B) high MOI, nor
do we see a notable difference in infection of MEFs after 14 hours. Means were compared by
Student t-test. (*, P < 0.05; **, P < 0.01; ***, P < 0.001).
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Figure 2.12

Figure 2.12. Lamp3 does not protect against early viral CHIKV titers in the tissues. 4 week
old WT and Lamp3-/- mice were injected with 1000 FFU of CHIKV-LR and were sacrified at 1
day post infection. Viral burdens in the serum, spleen, ankles, and quadriceps were analyzed by
focus forming assay. No statistical differences were identified by Mann-Whitney.

	
  

	
  50	
  

Figure 2.13

Figure 2.13. Lamp3 does not affect the chronic burden of CHIKV in mice. 4 week old mice
were infected with 1000 FFU of CHIKV-LR and harvested at 21 days post infection. Viral
burden in the ankles and the spleen were determined by quantitative PCR. No statistical
difference was observed by Mann-Whitney.
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Table 2.1. Final list of CHIKV and LACV antiviral ISGs identified from the shRNA screen
CHIKV
Symbol
Agt

targets
Full Name
Angiotensinogen

Akt3

Thymoma viral
proto-oncogene 3

Atf3
Ccng1

Activating
transcription factor 3
Cyclin G1

Cd47

CD47 antigen

Cfb
Dock4

Complement factor B
Dedicator of
cytokinesis 4

Erlec1

RIKEN cDNA
4933407N01
Family with sequence
similarity 129,
member A
GTP binding protein
2
Interferon activated
gene 202B
Interferon gamma
inducible protein 47
Kelch repeat and
BTB (POZ) domain
containing 8
Lysosomal-associated
membrane protein 3
Leucine
aminopeptidase 3

Fam129a
Gtpbp2
Ifi202b
Ifi47
Kbtbd8
Lamp3
Lap3
Lypla1

Lysophospholipase 1

Ppp2r2a

Protein phosphatase
2, regulatory subunit
B, alpha isoform
Receptor accessory
protein 3

Reep3

Tmod3

	
  

Tropomodulin 3

Known functions (NCBI)
Cleaved by renin in response to lowered blood pressure to form
angiotensin-1.
Serine/threonine kinase that plays a key in regulating cell survival,
insulin signaling, angiogenesis and tumor formation. Akt is a
downstream mediator of the PI 3-K pathway, which results in the
recruitment of Akt to the plasma membrane.
Binds cAMP. Represses transcription from promoters with ATF sites.
May play a role in growth regulation. Is associated with G2/M phase
arrest in response to DNA damage. May be an intermediate by which
p53 mediates its role as an inhibitor of cellular proliferation
Cell adhesion receptor on platelets. Modulation of integrins. May be
involved in membrane permeability changes induced following virus
infection.
Component of the alternative complement pathway.
Involved in regulation of adherens junction between cells. Plays a role
in cell migration. Functions as a guanine nucleotide exchange factor
(GEF), which activates Rap1 small GTPase by exchanging bound
GDP for free GTP.
N-glycan recognition in the ER and may regulate glycoprotein traffic
Regulates phosphorylation of a number of proteins involved in
translation regulation including EIF2A, EIF4EBP1 and RPS6KB1.
May be involved in the endoplasmic reticulum stress response
Upregulated in mouse peritoneal macrophages.
Unknown function
Unknown function
Unknown function
May play a role in dendritic cell function and in adaptive immunity.
Presumably involved in the processing and regular turnover of
intracellular proteins. Catalyzes the removal of unsubstituted Nterminal amino acids from various peptides.
Hydrolyzes fatty acids from S-acylated cysteine residues in proteins
such as trimeric G alpha proteins or HRAS. Has depalmitoylating
activity toward KCNMA1. Has low lysophospholipase activity
one of the four major Ser/Thr phosphatases, and it is implicated in the
negative control of cell growth and division
Microtubule-binding protein required to ensure proper cell division
and nuclear envelope reassembly by sequestering the endoplasmic
reticulum away from chromosomes during mitosis. Probably acts by
clearing the endoplasmic reticulum membrane from metaphase
chromosomes.
Blocks the elongation and depolymerization of the actin filaments at
the pointed end. The Tmod/TM complex contributes to the formation
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Trim34a
Trim69

Tripartite motifcontaining 34a
Tripartite motifcontaining 69

of the short actin protofilament, which in turn defines the geometry of
the membrane skeleton
Unknown function
The mouse ortholog of this gene is specifically expressed in germ
cells at the round spermatid stages during spermatogenesis and, when
overexpressed, induces apoptosis. Alternatively spliced transcript
variants encoding distinct isoforms have been described.

LACV

targets

Symbol

Full Name

Known functions (NCBI)

Agt

Angiotensinogen

Cleaved by renin in response to lowered blood pressure to form
angiotensin-1.

Btc

Betacellulin

Growth factor that binds to EGFR, ERBB4 and other EGF receptor
family members. Potent mitogen for retinal pigment epithelial cells
and vascular smooth muscle cells.

Ccdc50

Coiled-coil domain
containing 50

Involved in EGFR signaling. Mutations cause hearing loss in mice.

Dhx58

DEHX box
polypeptide 58

Acts as a regulator of DDX58/RIG-I and IFIH1/MDA5 mediated
antiviral signaling. Cannot initiate antiviral signaling as it lacks the
CARD domain required for activating MAVS/IPS1-dependent
signaling events.

Gbp3

Guanylate binding
protein 3

Specifically bind guanine nucleotides (GMP, GDP, and GTP) and
contain two of the three consensus motifs found in typical GTPbinding proteins. Exhibits antiviral activity against influenza virus.

Gbp4

Guanylate binding
protein 4

Binds GTP, GDP and GMP. Hydrolyzes GTP very efficiently; GDP
rather than GMP is the major reaction product. Plays a role in
erythroid differentiation

Htr1d

serotonin receptor 1D

G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also
functions as a receptor for ergot alkaloid derivatives, various
anxiolytic and antidepressant drugs and other psychoactive
substances. May play a role in vasoconstriction

Ifi203

Interferon activated
protein 203

Unknown function

Ifi47

Interferon gamma
inducible protein 47

Unknown function

Igtp

Interferon gamma
induced GTPase

Unknown function

Lypla1

Lysophospholipase 1

Hydrolyzes fatty acids from S-acylated cysteine residues in proteins
such as trimeric G alpha proteins or HRAS. Has depalmitoylating
activity toward KCNMA1. Has low lysophospholipase activity

Mov10

Moloney leukemia

Probable RNA helicase. Required for RNA-mediated gene silencing
by the RNA-induced silencing complex (RISC). Required for both
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virus 10

miRNA-mediated translational repression and miRNA-mediated
cleavage of complementary mRNAs by RISC. Also required for
RNA-directed transcription and replication of the human hepatitis
delta virus (HDV).

Pnpt1

Polyribonucleotide
protein
nucleotidyltransferase
1

RNA-binding protein implicated in numerous RNA metabolic
processes.

Psmb8

Proteasome subunit,
beta type 8

Replacement of PSMB5 by PSMB8 increases the capacity of the
immunoproteasome to cleave model peptides after hydrophobic and
basic residues. Acts as a major component of interferon gammainduced sensitivity. Plays a key role in apoptosis via the degradation
of the apoptotic inhibitor MCL1. May be involved in the
inflammatory response pathway.

Rps3a

Ribosomal protein
S3A

May play a role during erythropoiesis through regulation of
transcription factor DDIT3

Rtp4

Receptor transporter
protein 4

Probable chaperone protein which facilitates trafficking and
functional cell surface expression of some G-protein coupled
receptors (GPCRs). Promotes functional expression of the bitter taste
receptor TAS2R16

Samd9l

Sterile alpha motif
domain containing 9like

Unknown function

Sema6d

Semaphorin 6D

Shows growth cone collapsing activity on dorsal root ganglion (DRG)
neurons in vitro. May be a stop signal for the DRG neurons in their
target areas, and possibly also for other neurons. May also be involved
in the maintenance and remodeling of neuronal connections.

Serping1

Complement 1
inhibitor

forms a proteolytically inactive stoichiometric complex with the C1r
or C1s proteases. May play a potentially crucial role in regulating
important physiological pathways including complement activation,
blood coagulation, fibrinolysis and the generation of kinins.

Slc16a4

Solute carrier family
16, member 4

Proton-linked monocarboxylate transporter. Catalyzes the rapid
transport across the plasma membrane of many monocarboxylates
such as lactate, pyruvate, branched-chain oxo acids derived from
leucine, valine and isoleucine, and the ketone bodies acetoacetate,
beta-hydroxybutyrate and acetate

Slc25a28

Solute carrier family
25, member 28

Mitochondrial iron transporter that mediates iron uptake.

Snx5

Sorting nexin 5

Involved in several stages of intracellular trafficking.

Sp100

Nuclear antigen
Sp100

involved in a large number of physiological processes including cell
growth, differentiation and apoptosis.

Tgm2

Transglutaminase 2

Catalyzes the cross-linking of proteins and the conjugation of
polyamines to proteins.
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Trim25

Tripartite motifcontaining 25

Expression of the gene is upregulated in response to estrogen, and it is
thought to mediate estrogen actions in breast cancer as a primary
response gene.

Ttc39b

Tetratricopeptide
repeat domain 39b

Unknown function

Ubd

Ubiquitin D

Constitutively expressed in mature dendritic cells and B-cells. Mostly
expressed in the reticuloendothelial system (e.g. thymus, spleen), the
gastrointestinal system, kidney, lung and prostate gland

Ugt1a6a

UDP
glycosyltransferase

UDPGT is of major importance in the conjugation and subsequent
elimination of potentially toxic xenobiotics and endogenous
compounds. This isoform has specificity for phenols. Isoform 3 lacks
transferase activity but acts as a negative regulator of isoform 1

Xdh

xanthine
dehydrogenase

Key enzyme in purine degradation. Catalyzes the oxidation of
hypoxanthine to xanthine. Catalyzes the oxidation of xanthine to uric
acid. Contributes to the generation of reactive oxygen species. Has
also low oxidase activity towards aldehydes

Zeb2

Zinc finger E-box
binding homeobox 2

Transcriptional inhibitor that binds to DNA sequence 5-CACCT-3 in
different promoters. Represses transcription of E-cadherin.
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Table 2.2. sgRNAs for select ISGs to generate bulk CRISPR knockout cell lines.
Gene
Name

CRISPR
line

Sequence 5'-->3'

Gene
Name

CRISPR
line

Sequence 5'-->3'

Stat1

1

caccgGGATAGACGCCCAGCCACTG

Kbtbd8

1

caccgCCTGTGACGATATCTAGACA

aaacCAGTGGCTGGGCGTCTATCCc

2

aaacTGTCTAGATATCGTCACAGGc

2

caccgTGTGATGTTAGATAAACAGA
aaacTCTGTTTATCTAACATCACAc

3

aaacCATTTAAATCGTCACTGTCTc

3

caccgCGGCTGTCGTTCTACCACGA
aaacTCGTGGTAGAACGACAGCCGc

Ccng1

1

caccgGGATCAAATCAGTCGCCAGT

Lamp3

1

2

caccgGGAGTCTAGATGTCAGCCAA

1

3

caccgACGACACCTTGCCATTTGAG

caccgCCAGGCCAGTTGACTCGGAA

Ifi202b

1

2

caccgACTTCCACTTGTGACAAGTG

1

3

caccgTCCAACTGTCTTAGTGTGAG

caccgCCAGCGCAGAGGACATCCGA

Ifi47

1

2

caccgTCCTCAAATACCAGTGACCC

	
  

1

3

caccgTACCGTCAACAACAGACCCC

caccgATTGTAACTTACTCCAAACC

caccgTTGGAGATCAGGAAGATGCA
aaacTGCATCTTCCTGATCTCCAAc

aaacGGGGTCTGTTGTTGACGGTAc

Fam129a

caccgGGTCTAGATAAGCGTCTGCG
aaacCGCAGACGCTTATCTAGACCc

aaacGGGTCACTGGTATTTGAGGAc

3

caccgTGGCCAGATGAATCACTGGA
aaacTCCAGTGATTCATCTGGCCAc

aaacTCGGATGTCCTCTGCGCTGGc

2

caccgCCAAAAAAGAACATTAGCAA
aaacTTGCTAATGTTCTTTTTTGGc

aaacCTCACACTAAGACAGTTGGAc

Atf3

caccgGGGAAACCAATATTACACTC
aaacGAGTGTAATATTGGTTTCCCc

aaacCACTTGTCACAAGTGGAAGTc

3

caccgTCATCTACTGACGATACCAT
aaacATGGTATCGTCAGTAGATGAc

aaacTTCCGAGTCAACTGGCCTGGc

2

caccgCCCAGTTATATAGTTGACAA
aaacTTGTCAACTATATAACTGGGc

aaacCTCAAATGGCAAGGTGTCGTc

Erlec1

caccgAGAGTAGGCCTAGGAACTAG
aaacCTAGTTCCTAGGCCTACTCTc

aaacTTGGCTGACATCTAGACTCCc

3

caccgAAGACTCCAATAGAATTCTG
aaacCAGAATTCTATTGGAGTCTTc

aaacACTGGCGACTGATTTGATCCc

2

caccgAGACAGTGACGATTTAAATG

caccgCTGATTAATGCAGAGTACTG
aaacCAGTACTCTGCATTAATCAGc

Lypla1
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1

caccgTTCACGGATTGGGAGATACA

aaacGGTTTGGAGTAAGTTACAATc

2

aaacTGTATCTCCCAATCCGTGAAc

2

caccgACGGAGCTTAACCTTCTCGA
aaacTCGAGAAGGTTAAGCTCCGTc

3

aaacCCCGGAAGGCCACCGCCGCGc

3

caccgCAGACCTCAAAACCGCCATG
aaacCATGGCGGTTTTGAGGTCTGc

Gtpbp2

1

caccgCCAGTTCCTAGATCTCCGTG

Lap3

1

2

caccgACTGGACAGTGTAAATATAG

1

3

caccgCCTGTGTGCTAAGACCACAG

caccgCCATATTGGAGATCACTAGT

Ppp2r2a

1

2

caccgGGTAGCGGGTAGTATCCTGA

1

3

caccgATGAAATCCTCGATCTGCGA

caccgTATGACGGTTACACTCTCCG

Trim69

1

2

caccgCATGTACGACACCCCTCAAG

1

3

caccgTCTGCAGGATTGCACAACAT

caccgGGAAGGGGTGGATGTATACG

Tmod3

1

caccgTTCGGTTAGCACCGACCTCG
aaacCGAGGTCGGTGCTAACCGAAc

2

caccgTGGATAAATCCAGAGAGCGT
aaacACGCTCTCTGGATTTATCCAc

	
  

caccgAGGATGCACGGTTGTCTATG
aaacCATAGACAACCGTGCATCCTc

aaacCGTATACATCCACCCCTTCCc

2

caccgAAGAAGTTACCCCTGCTCAA
aaacTTGAGCAGGGGTAACTTCTTc

aaacATGTTGTGCAATCCTGCAGAc

Agt

caccgCGGAACCAGTCGTTACACAG
aaacCTGTGTAACGACTGGTTCCGc

aaacCTTGAGGGGTGTCGTACATGc

3

caccgGATGTGATAAGTGTGGGCGT
aaacACGCCCACACTTATCACATCc

aaacCGGAGAGTGTAACCGTCATAc

2

caccgCAAACGTGTTACAGCTGTTG
aaacCAACAGCTGTAACACGTTTGc

aaacTCGCAGATCGAGGATTTCATc

CFB

caccgAAAAGAGGAACACTTACCGT
aaacACGGTAAGTGTTCCTCTTTTc

aaacTCAGGATACTACCCGCTACCc

3

caccgAAGTGCCAGTAGTAAAACCA
aaacTGGTTTTACTACTGGCACTTc

aaacACTAGTGATCTCCAATATGGc

2

caccgGTCCACCGCAGACATGACGA
aaacTCGTCATGTCTGCGGTGGACc

aaacCTGTGGTCTTAGCACACAGGc

Dock4

caccgGGGGTGCCTCGGTTGCATTG
aaacCAATGCAACCGAGGCACCCCc

aaacCTATATTTACACTGTCCAGTc

3

caccgTGGACAGATGTATTTGATGT
aaacACATCAAATACATCTGTCCAc

aaacCACGGAGATCTAGGAACTGGc

2

caccgCGCGGCGGTGGCCTTCCGGG

caccgTGTAGGGCACATAATCGTCC
aaacGGACGATTATGTGCCCTACAc
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3

3

caccgCTCCCGACTAGATGGACACA
aaacTGTGTCCATCTAGTCGGGAGc

Akt3

1

aaacTTACTACTTCCCAGCACATCc

Reep3

caccgCCGTAGCCGACCGATTGCAG

1

aaacCTGCAATCGGTCGGCTACGGc

2

2

caccgAATTTGATGCTAGATAAGGA

1

3

caccgCTGCACCATAGAAACGTGTG

Trim34a

caccgATCAGCCTGTTCTTACGAGG

1

2

caccgGGATAAGCGCGATGCCATGG

1

3

caccgCACTTCATGCAATGAAACTG

Ifitm3

caccgACGGAGGCTAACGTCGCAA

1

caccgCTGACAGAAGCCGATCCGTG
aaacCTCGGATCGGCTTCTGTCAGc

2

caccgCGCTTCCGCGCGGCCCGTTCAA
aaacTTGAACGGGCCGCGCGGAAGCGc

3

caccgGCTTAGAAGAATCCTGGACA
aaacTGTCCAGGATTCTTCTAAGCc

aaacTTGCGACGTTAGCCTCCGTc

2

caccgGAGAATCTAGTACCACACAC
aaacGTGTGTGGTACTAGATTCTCc

aaacCAGTTTCATTGCATGAAGTGc

negative
control

caccgGACAGGCTTGGCATACACGG
aaacCCGTGTATGCCAAGCCTGTCc

aaacCCATGGCATCGCGCTTATCCc

3

caccgATCTTCAGCTCATAGTACAG
aaacCTGTACTATGAGCTGAAGATc

aaacCCTCGTAAGAACAGGCTGATc

2

caccgGCTGTCGCCCTACACTAGAG
aaacCTCTAGTGTAGGGCGACAGCc

aaacCACACGTTTCTATGGTGCAGc

CD47

caccgCGTGAAGACGAAAAACGTCA
aaacTGACGTTTTTCGTCTTCACGc

aaacTCCTTATCTAGCATCAAATTc

3

caccgGATGTGCTGGGAAGTAGTAA

aaacCCTCATATTCTTCCTTGATTc

3

caccgATCGTTTCCGCTTAACGGCG
aaacCGCCGTTAAGCGGAAACGATc

caccgAATCAAGGAAGAATATGAGG

caccgGTCTAGGGATCGGAAGATGG
aaacCCATCTTCCGATCCCTAGACc

Sequences in bold correspond to the sgRNA oligo. Nucleotides in lower case correspond to the
flanking sequence required to ligate the oligos to the LentiCRISPRv2 vector.
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Chapter 3: Characterization of murine Ifitm3 as an antiviral ISG against alphaviruses in
vitro and in vivo

This chapter is essentially as published in Journal of Virology:
“The Interferon-Stimulated Gene IFITM3 Restricts Infection and Pathogenesis of Arthritogenic
and Encephalitic Alphaviruses” Poddar S, Hyde JL, Gorman MS, Farzan M and Diamond MS.
October 2016, vol 90, no.19 8780-8794.
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ABSTRACT
Host cells respond to viral infections by producing type I interferon (IFN), which induces
the expression of hundreds of interferon stimulated genes (ISGs). Although ISGs mediate a
protective state against many pathogens, the antiviral functions of the majority of these genes
have not been identified. IFITM3 is a small transmembrane ISG that restricts a broad range of
viruses including orthomyxoviruses, flaviviruses, filoviruses, and coronaviruses. Here, we show
that alphavirus infection is increased in Ifitm3-/- and Ifitm locus deletion (Ifitm-del) fibroblasts,
and reciprocally, reduced in fibroblasts trans-complemented with Ifitm3. Mechanistic studies
showed that Ifitm3 did not affect viral binding or entry, but inhibited pH-dependent fusion. In a
murine model of chikungunya virus arthritis, Ifitm3-/- mice sustained greater joint swelling in the
ipsilateral ankle at days 3 and 7 post infection, and this correlated with higher levels of proinflammatory cytokines and viral burden. Flow cytometric analysis suggested that Ifitm3-/macrophages from the spleen were infected at greater levels than observed in wild-type (WT)
mice, results that were supported by experiments with Ifitm3-/- bone marrow derived
macrophages. Ifitm3-/- mice also were more susceptible than WT mice to lethal alphavirus
infection with Venezuelan equine encephalitis virus, and this was associated with greater viral
burden in multiple organs. Collectively, our data define an antiviral role for Ifitm3 in restricting
infection of multiple alphaviruses.
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INTRODUCTION
The type I interferon (IFN) response is a critical factor that orchestrates innate protection
against viral pathogens. Upon detection of pathogen-associated molecular patterns (PAMPs),
host cells produce type I IFN, which in turn induces expression of hundreds of IFN stimulated
genes (ISGs). ISGs can inhibit multiple steps of the viral life cycle (e.g. entry, protein translation,
assembly, or egress) or modulate the immune response, such as by enhancing the recruitment of
leukocytes or promoting B and T cell maturation (14).
IFN-induced transmembrane (IFITM) proteins 1, 2 and 3 were among the first IFNstimulated genes (ISGs) to be identified (92), and initially were studied for their roles in germ
cell homing and maturation. IFITM proteins are approximately 130 amino acids in length, and
are conserved in most vertebrate species (93). IFITMs have no catalytic subunit, but share
similar domain architectures consisting of a short N-terminal domain, two antiparallel domains, a
conserved intracellular loop, and a hydrophobic C-terminal domain (94, 95). The topology of
IFITM3 has been clarified by electron paramagnetic and nuclear magnetic resonance analyses;
the N-terminal is located inside the cell, whereas the antiparallel domains reside as
intramembrane α-helices, followed by the transmembrane C-terminal domain (96). Although
IFITM1, 2, and 3 all have reported antiviral activity, IFITM3 exhibits the greatest protection
against the broadest range of viruses including influenza A virus (IAV), flaviviruses (Dengue,
West Nile, and Japanese encephalitis viruses), hepaciviruses (hepatitis C virus), filoviruses
(Ebola and Marburg viruses), bunyaviruses (Rift Valley Fever and La Crosse viruses),
rhabdoviruses (vesicular stomatitis virus), coronaviruses (SARS-CoV), paramyxoviruses
(respiratory syncytial virus, RSV), and reoviruses (9, 56, 60, 61, 64, 66, 68–70, 97, 98). Despite
a wealth of in vitro data, the antiviral effects of IFITM3 in vivo are less well characterized. To
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date, only IAV and RSV have been shown to have enhanced pathogenesis in Ifitm3-deficient
(Ifitm3-/-) mice (59, 63, 64). In humans, the allelic polymorphism rs12252-C, which results in a
splice variant of IFITM3 lacking the first 21 amino-terminal amino acids, correlates with
increased morbidity and mortality following IAV infection (63, 99, 100). However, some studies
have questioned the significance of this truncated IFITM3 allele in the susceptibility to IAV and
other viral infections (80, 81).
The mechanisms by which IFITM3 restrict viral infection are not fully elucidated.
Studies have shown that IFITM3 affects pH dependent fusion in the late endosome, which
potentially traps entering virions in a hemifusion state (57, 78, 101). IFITM3 expression also can
modulate the efficiency of cathepsin-mediated proteolysis in an as yet undefined manner, which
is required for the cleavage of the fusion proteins of reoviruses, filoviruses, and coronaviruses,
and release of the viral genome from the endolysosome into the cytosol (56, 69). Additionally,
IFITM3 is incorporated into the plasma membrane of budding HIV particles, which restricts their
fusogenic capability (72). Finally, ectopic expression of IFITMs appears to alter the physical
characteristics of the endosome, resulting in increased size, reduced membrane fluidity, and
increased cholesterol content, which subsequently impact the efficiency of viral fusion (52, 78,
79).
Alphaviruses are enveloped single-stranded positive sense RNA viruses of the
Togaviridae family, many of which are transmitted by mosquitoes. The binding, entry, and pHdependent fusion of alphaviruses are directed by the structural glycoproteins E1 and E2 (102,
103). E1 and E2 are arranged as heterodimers, and assembled into trimeric spikes on the surface
of the virion (104). E1 is classified as a type II membrane fusion protein, whereas E2 contains
the putative receptor binding site (102).
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Chikungunya virus (CHIKV) has emerged rapidly over the last decade, causing outbreaks
in the islands of the Indian Ocean, in Southern Europe, and in Southeast Asia. In 2013, CHIKV
spread to the Western Hemisphere and by the end of 2015 had infected more than 1.8 million
people in North, Central, and South America (30). Other arthritogenic alphaviruses have a more
limited distribution in parts of Oceania, Africa, and South America, whereas outbreaks of
encephalitic alphaviruses occur sporadically in North, Central, and South America (105).
Infection by arthritogenic alphaviruses, including CHIKV, Sindbis, Ross River, and Mayaro
viruses, results in a febrile illness associated with rash, myalgia, and moderate to severe joint
pain (41). The musculoskeletal disease caused by these viruses is associated with direct infection
of myocytes, synovial fibroblasts and osteoblasts (32, 34, 38, 39, 41) and the ensuing infiltration
of inflammatory cells. Infection by encephalitic alphaviruses, including Venezuelan (VEEV),
Eastern, and Western equine encephalitis viruses, causes a severe febrile illness associated with
infection and injury to neurons, encephalitis, long-term debilitating neurological sequelae, and
death (105). To date, there are no licensed alphavirus vaccines available for use in humans.
Several ISGs have been characterized as restriction factors against alphavirus infection,
including ISG15, PKR, ZAP and BST-2; these genes target viral protein translation and virion
egress, respectively (15–17, 19, 46). Ectopic expression-based screens against alphaviruses also
have revealed putative inhibitory genes, including Isg20, Ifit1, Ifit2, Ifit3, and Rsad2 (47).
However, in the case of Ifit1, which recognizes RNA lacking a 2'-O methylation on the 5' cap
structure and prevents translation, alphaviruses subvert its antiviral function via RNA secondary
structure motifs that inhibit binding (48). Recent studies suggest that ectopic expression of
IFITM genes in cell culture can restrict infection of Sindbis (SINV) and Semliki Forest (SFV)
viruses in cell culture by inhibiting viral fusion with cellular membranes (106). Other ISGs (e.g.,
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HSPE and P2RY6), have been identified, with little information regarding their mechanism of
restriction (7, 20). Finally, ISGs can act in synergy to inhibit alphavirus infection (45).
In this study, we evaluated the antiviral activity of IFITM3 against several alphaviruses
by comparing infection of IFN-treated wild-type (WT), Ifitm3-/-, and Ifitm locus deletion (Ifitmdel) mouse fibroblasts with CHIKV, SFV, SINV, O'nyong nyong (ONNV), and VEEV viruses.
In the absence of Ifitm3 gene expression we observed an increase in alphavirus replication in
vitro, which was inhibited following trans-complementation with Ifitm3. In vivo, Ifitm3-/- mice
inoculated with CHIKV sustained higher viral burden in the spleen, serum, and joint tissues at
early times after infection. This was associated with higher levels of pro-inflammatory cytokines
and increased joint swelling along with greater replication in macrophages in some tissues.
Consistent with this latter observation, bone marrow derived macrophages from Ifitm3-/- mice
sustained higher levels of CHIKV infection than WT cells. Analogous to our observed
phenotypes with CHIKV in vivo, Ifitm3-/- mice infected with VEEV exhibited greater weight loss
and mortality, and supported greater replication in the liver, spleen, spinal cord, and brain.
Collectively, our data suggest that Ifitm3 contributes to an early host defense response against
multiple alphaviruses of global concern.
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MATERIALS AND METHODS
Ethics statement. This study was carried out in accordance with the recommendations in
the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The
protocols were approved by the Institutional Animal Care and Use Committee at the Washington
University School of Medicine (Assurance Number: A3381-01). Dissections and injections were
performed under anesthesia that was induced with ketamine hydrochloride and xylazine.
Mice. WT C57BL/6 mice were obtained commercially from Jackson Laboratories. Ifitmdel and Ifitm3-/- mice have been reported previously (107). Ifitm2-/- mice will be described in a
forthcoming manuscript (M. Gorman and M. Diamond, unpublished data). All transgenic mice
were backcrossed to 99% purity using speed congenic analysis (108). Four week-old mice were
inoculated in the left footpad with 103 FFU of CHIKV-LR in 10 µl of PBS. Ankles were
measured (width x height) for joint swelling on days 3 and 7 post infection. On selected days
after infection, mice were sacrificed for the collection of serum and tissues. After intracardiac
perfusion with PBS, organs were harvested, weighed and homogenized to determine viral titers
by a focus forming assay. For studies with VEEV, a vaccine-derived recombinant strain with a
point mutation (TC83-A3G) was used; this mutation confers partial virulence in WT mice as it
restores the capacity to antagonize the inhibitory actions of the ISG, Ifit1 (48). Four week-old
mice were inoculated in the left footpad with 106 FFU of VEEV-TC83-A3G in 10 µl of PBS.
Mice were followed daily for survival and weighed every two days. On selected days, infected
mice were sacrificed and organs were harvested as described above.
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Flow cytometric analysis of CHIKV-infected splenocytes. Spleens of CHIKV-infected
mice were harvested after perfusion with PBS. Splenocytes were obtained by generating a single
cell suspension, passaging through a 70 µm filter, and lysis of red blood cells with ACK buffer
(Invitrogen). Splenocytes were maintained on ice in PBS supplemented with 2% FBS and 1 mM
EDTA. After blockade of Fcγ receptors with anti-CD16/32 (eBioscience Clone 93), staining for
viability (eBioscience FVD eFluor 506), and cell surface antigens CD45, CD3, CD19, CD3,
Ly6G, Ly6C, CD11b, CD11c, MHC class II, and F4/80 was performed. Viral antigen (E1 and E2
proteins on the surface of cells) was detected using biotinylated humanized CHK-152 and
murine CHK-166 (37), with biotinylated humanized WNV E16 and murine WNV E60 (109,
110) serving as isotype controls, respectively. Secondary staining was followed with streptavidin
conjugated Alexa 647 (Invitrogen). Cells were fixed subsequently using the eBioscience FoxP3
Fixation Buffer Set and processed for flow cytometry with the BD LSRII. Data were analyzed
with FloJo software.
Bioplex cytokine assay. To measure cytokine levels, a BioPlex Pro Assay was
performed according to the manufacturer's protocol (BioRad) on homogenized ankle tissues
isolated at day 1 and 2 post infection. The cytokine screen included IL-1α, IL-1β, IL-2, IL-3 IL4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, Eotaxin, G-CSF, GM-CSF, IFN-γ,
KC, MCP-1 MIP-1α, MIP-1β, RANTES (CCL5), and TNF-α.
Cells and viruses. Primary WT, Ifitm-del, Ifitm2-/- and Ifitm3-/- derived mouse embryonic
fibroblasts (MEFs) and bone marrow derived macrophages were generated according to
published methods (111). Transformed MEFs were generated by transfection of the SV2
plasmid, which encodes for the large T antigen of SV2 polyoma virus (112), and passaged ~10
times. All MEFs were cultured in complete DMEM, which was supplemented with 10% fetal
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bovine serum, and 10 mM each of GlutaMAX, sodium pyruvate, non-essential amino acids and
HEPES pH 7.3. MEFs that ectopically express c-Myc-tagged firefly luciferase or c-Myc-tagged
Ifitm3 were generated via lentiviral transduction of the pFCIV vector, which contains an IRESGFP (113, 114). Lentivirus was produced by transfecting 293T cells with pSPAX.2 (Addgene
12260), pMD2G (Addgene 12259) and pFCIV. Supernatants were harvested at 48 to 72 h post
transfection. WT, Ifitm-del and Ifitm3-/- transformed MEFs were incubated with lentiviral
supernatants and 10 µg/ml of polybrene and spinoculated (300 x g) at room temperature for 30
min. The inoculum was replaced with complete DMEM 24 h later and incubated at 37°C.
Transduction efficiency was determined by expression of GFP, and sorting of GFP+ cells was
performed on a FACS AriaII (Becton-Dickinson). After repeated passages to ensure stable
expression, the MEFs were tested for GFP and protein expression by flow cytometry and
Western blotting, respectively. Vero and 293T cells were cultured and passaged in complete
DMEM.
The CHIKV-LR (La Reunion OPY1 p142) strain was a gift from S. Higgs (Kansas State
University). SINV (Toto) was a gift from C. Rice and P. MacDonald (Rockefeller University).
VEEV-TC83 was a gift from W. Klimstra (University of Pittsburgh). These strains were
produced from infectious cDNA clones (115, 116). CHIKV 181/25, ONNV (MP30), SFV
(Kumba), were provided by the World Reference Center for Arboviruses (R. Tesh, University of
Texas Medical Branch). Virus propagation and titration was performed in Vero cells.
Genotyping of MEFs. Genomic DNA was extracted from MEFs with the Qiagen
DNeasy Blood and Tissue kit, and was characterized by PCR. Ifitm2 WT allele or the knockout
construct

was

genotyped

using

the

following

primers:

Ifitm2

WT

F:

5'-

ATGTGGTCTGGTCCCTGTTC-3', Ifitm2 WT R: 5'-AGGTGCTCTGGCTCCATTTC-3'; WT
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band = 520 bp. Ifitm2 KO F: 5'-TCATTCTCAGTATTGTTTTGCC-3', Ifitm2 KO R: 5'TGGAGACCAGAAGCCTGAC-3'; KO band = 373 bp. PCR reaction conditions for both Ifitm2
WT and KO alleles were as follows: 94°C for 3 min, 94°C for 45 s, 55°C for 30 s, 70°C for 1
min 30 s, 35 cycles, and 70°C for 10 min. The Ifitm3-/- mouse can be identified by the in-frame
insertion of GFP within the Ifitm3 allele (C Bailey, unpublished)(107).
knockout construct was genotyped using the following primers:

WT allele or the
WT Ifitm3 F: 5'-

ATCCTTTGCCCTTCAGTGCT-3' and WT Ifitm3 R: 5'-ACTCATACCTCGGTGCCATC-3';
WT band = 355 bp, KO band = 1321 bp. PCR reaction conditions for both Ifitm3 WT and KO
were as follows: (a) 94°C for 1 min 30 s, 94°C for 25 s, 60°C for 30 s, reducing temperature by
0.1°C per cycle, 72°C for 1 min 30 s, 35 cycles, and 72°C for 5 min. The IFITM-del allele was
determined

using

the

following

primers

(107):

AACATGCCTTGCATCCCTGGAGTTCCTTCTAAAGGA-3',

IFITM-del
IFITM-del

WT

F:

5'-

WT

R:

5'-

CCCTAAAACACTTAGCAGTGACCCCTCACAAGCC-3'; WT band = 500bp. Ifitm-del KO F:
5'-ACTCTAGCCAGAGTCTTGCATTTCTCAGTCCTAAAC-3',

IFITM-del

KO

R:

5'-

TCTAGTACAGTCGGTAAGAACAAAATAGTGTCTATC A-3'; KO band = 600bp. PCR
reaction conditions for Ifitm-del alleles were as follows: 95°C for 30 s, 54°C for 30 s, 68°C for 1
min 30 s, 29 cycles, and 68°C for 5 min.
qRT-PCR measurement of Ifitm genes. WT, Ifitm2-/-, Ifitm3-/- and Ifitm-del MEFs (104
cells per condition) were seeded in a 96-well plate. After a 6 h incubation with IFN-β at varying
doses, MEFs were lysed and total RNA was extracted with the Qiagen RNeasy Kit. Ifitm2 and
Ifitm3 were detected using qRT-PCR and normalized to Gapdh expression, using the following
PrimeTime

assays

(IDT)

according

to

the

manufacturer’s

instructions:

Mm.PT.58.33172327.g, Ifitm3: Mm.PT.51.6979575.g, and Gapdh: Mm.PT.39a.a.
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Ifitm2:

Western blotting. MEFs were lysed in RIPA and electrophoresed under reducing
conditions on a 12% Bis-Tris NuPAGE gel with MES buffer according to the manufacturer’s
instructions (Thermo Fisher). After transfer onto PVDF membranes (Thermo Fisher) using an
iBlot apparatus (Thermo Fisher), proteins of interest were detected with mouse anti-b-actin
(CST, 8H10D10), mouse anti-c-Myc (Sigma, 9E10), goat anti-Ifitm3 (R & D, AF337), HRPconjugated anti-mouse IgG (Sigma Chemical), and HRP-conjugated anti-goat IgG (Santa Cruz,
sc2304). For quantification of protein, secondary donkey anti-mouse IRDye 680 (Li-Cor 92568072) and anti-rabbit- IRDye 800CW (Li-Cor, 926-32214) were used instead of HRP
conjugates, and visualized on the Odyssey Imager (Li-Cor). Polyclonal rabbit anti-Ifitm3
(Proteintech, 11714-1-AP) was used for Ifitm3 detection in these experiments. Quantification
was performed with Li-Cor Odyssey software.
Virus infection of cells. MEFs were plated (104 cells per well) in a 96-well plate, and in
some experiments pretreated for 6 h with recombinant mouse IFNβ (PBL Assay Science) at
concentrations from 5 to 0.1 IU/ml, as indicated in the Figure Legends. The cells were inoculated
with a given alphavirus (multiplicity of infection (MOI) of 5) and incubated at 37°C. At selected
time points, cells were trypsinized, fixed with 1% paraformaldehyde (PFA), and permeabilized
with Hank’s Balanced salt solution (HBSS) containing 0.1% saponin and 10 mM HEPES.
Infection was determined after sequentially staining cells with mouse or human mAbs (CHIKV,
CHK-11; SFV, 2B4; TC83, 1A4A-1; ONNV, 4J21) (37, 117) against the E2 glycoprotein. SINV
infection was detected using murine anti-SINV ascites (ATCC, VR-1248AF). Alexa 647
conjugated goat-anti mouse or human IgG antibody (Life Technologies) was used for secondary
antibody staining. Samples were processed by flow cytometry using a BD FACSArray. Data
were analyzed with FloJo software.
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For viral yield assays, cells were plated (105 cells per well in a 12-well plate) and in some
experiments pretreated with specified doses of IFNβ for 12 hours. Cells then were infected with
CHIKV at 37°C. One hour later, the plates were rinsed twice with warm PBS, and replaced with
fresh DMEM supplemented with 10% FBS. Supernatants were collected at specific time points,
and viral titers were determined by focus forming assay on Vero cells, as described (37, 48).
After fixation, infected cell foci were detected with CHK-11 and HRP-conjugated anti-mouse
IgG (Sigma Chemical), and quantified with an ImmunoSpot (Cellular Technologies, Ltd.).
Binding and internalization assays. MEFs were plated (105 cells/well in a 24 well plate)
the night before use. Cells were chilled on ice for 10 min, exposed to CHIKV-LR at an MOI of
5, and incubated on ice for 1 h. Unbound virus was removed with repeated washes of chilled
media or PBS. To determine binding efficiency of virus, MEFs were lysed with RLT buffer and
RNA was extracted using the Qiagen RNeasy Mini Kit, and analyzed for CHIKV RNA by qRTPCR. To determine the efficiency of virus internalization, warm complete DMEM was added to
MEFs and incubated at 37°C for 1 hr. Medium was removed and cells were placed on ice.
Proteinase K (500 µg/ml) in ice cold PBS was added for 1 h to digest any surface bound virus
(118). MEFs were then transferred to eppendorf tubes and washed with PBS before lysing with
RLT buffer and extracting RNA for qRT-PCR. Primer probe sets were ordered from IDT were
CHIKV (F: 5'-TCGACGCGCCCTCTTTAA-3', R: 5'-ATCGAATGCACCGCACACT-3', Probe:
5'-/56-FAM/ACCAGCCTGCACCCATTCCTCAGAC/36-TAMSp/-3')

and

the

GAPDH

Primetime Assay Mm.PT.39a.a.
Fusion from without (FFWO) assay. MEFs were rinsed and then incubated with
DMEM, supplemented with 0.2% FBS, 10 mM HEPES pH 7.3 and 20 mM NH4Cl on ice for 15
min. Virus (MOI of 100) was added to MEFs on ice for one hour to allow binding. Unbound
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virus was removed after several rinses with chilled medium. Subsequently, pre-warmed acidic
(DMEM, 0.2% FBS, 10 mM HEPES, 30 mM succinic acid pH 5.5) or neutral (DMEM, 0.2%
FBS, 10 mM HEPES, pH 7.4) medium was added for 2 min at 37°C. Medium then was removed
and replaced with warmed DMEM, 10% FBS, 10 mM HEPES supplemented with 20 mM NH4Cl
to inhibit endosomal viral fusion and de novo infection via the endosomal pathway. At 6 h after
infection, MEFs were fixed with PFA, permeabilized, and analyzed for viral antigen by flow
cytometry, as described above.
Statistical analysis. All data was analyzed using Prism software (GraphPad6, San Diego,
CA). Viral infection assays in cell culture were analyzed by one-way ANOVA with Dunnett’s
multiple comparisons test, or Student’s t-test. Viral kinetics assays were analyzed by two-way
ANOVA with Dunnett’s or Sidak’s multiple comparisons. Viral burden assays were analyzed by
the Mann-Whitney test. Quantitative RT-PCR assays were analyzed by Student’s t-test. KaplanMeier survival curves were analyzed by the log rank test.
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RESULTS
Restriction of alphaviruses by Ifitm proteins in cell culture. Although expression of
IFITM genes inhibits infection of several different genera of viruses (9, 56, 60, 61, 64, 66, 68–
70, 97), their antiviral activities against alphaviruses have yet to be established. To test whether
Ifitm genes restrict alphavirus infection, we developed MEF lines lacking Ifitm2 (Ifitm2-/-),
Ifitm3 (Ifitm3-/-), and Ifitm1, 2, 3, 5, and 6 (Ifitm-del) (Fig 3.1A). To assess their effects on
CHIKV replication, MEFs were first pretreated with 1 IU/ml of recombinant mouse IFNβ to
induce Ifitm gene expression (Fig 3.1B). Ifitm3 protein induction was confirmed by Western
blotting in WT and Ifitm2-/- MEFs after IFNβ treatment, whereas, as expected, Ifitm3-/- and Ifitmdel MEFs lacked Ifitm3 protein (Fig 3.1C). IFN pretreated MEFs were then infected with a high
viral dose (MOI of 5) of pathogenic (CHIKV-La Reunion 2006 (LR)) or attenuated (CHIKV
181/25) strains of CHIKV. Fourteen hours later, cells were harvested, and viral antigen was
analyzed by flow cytometry. Whereas Ifitm3-/- and Ifitm-del MEFs supported greater CHIKV
infection (3-fold, P < 0.01 and 4-fold, P < 0.001 for CHIKV 181/25; 4.5-fold, P < 0.0001 and
6.5-fold, P < 0.0001 for CHIKV-LR) than WT cells, no increase in viral antigen expression was
observed in Ifitm2-/- MEFs (Fig 3.1D-F). Correspondingly, IFNβ pre-treated Ifitm3-/- and Ifitmdel MEFs infected with CHIKV produced higher titers of infectious virus compared to WT or
Ifitm2-/- cells (Fig 3.1G, CHIKV 181/25: 28-fold for Ifitm3-/- (P < 0.01), and 12-fold for Ifitm-del
(P < 0.05); Fig 3.1H, CHIKV-LR: 147-fold for Ifitm3-/- (P < 0.0001), and 36-fold for Ifitm-del
(P < 0.0001)) at 14 h post-infection. These data suggest that Ifitm3 has a dominant antiviral
effect on CHIKV infection compared to Ifitm2.
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We next tested whether Ifitm3 exhibited antiviral activity against other alphaviruses.
Analogous to experiments with CHIKV, WT and Ifitm-deficient MEFs were pre-treated with
varying doses of IFNβ, infected at a high MOI, and assayed by flow cytometry. Notably, Ifitm3-/and Ifitm-del MEFs pre-treated with IFNβ supported enhanced infection by SFV, ONNV, VEEV
(strain TC-83), and SINV compared to WT cells (P < 0.05, Fig 3.2).
To corroborate our findings, we trans-complemented WT, Ifitm3-/- and Ifitm-del MEFs
with c-myc tagged to the N-terminal of Ifitm3 or firefly luciferase protein as a control. After
confirmation of ectopic protein expression by flow cytometry and Western blotting (Fig 3.3A
and B), MEFs were infected with CHIKV 181/25 (MOI of 5) in the absence of IFNβ treatment
and analyzed at 6 h post-infection. MEFs trans-complemented with Ifitm3 showed less CHIKV
replication than firefly luciferase expressing controls (Fig 3.3C and D). This data suggests that
Ifitm3 inhibits multiple alphaviruses in vitro and does not require expression of Ifitm1, Ifitm2,
Ifitm5, and Ifitm6 proteins to exert its antiviral activity.
Ifitm3 inhibits pH-dependent fusion of alphaviruses. Studies with IAV have shown
that IFITM3 prevents fusion of virions from the late endosome, which is required for release of
viral genomic material into the cytosol (57, 101). Correspondingly, IFITM3 is expressed
preferentially on membranes of intracellular vesicles including endosomes (56). However,
following gene upregulation, such as after IFN induction or ectopic expression, IFITM3 can
accumulate on the plasma membrane (59, 62, 119), which independently could restrict
attachment of viruses to the cell surface. To define the stage in the alphavirus lifecycle that
Ifitm3 inhibits, we assessed its effect on binding, internalization, and fusion.
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To determine if expression of Ifitm3 alters binding of alphaviruses to the cell surface,
trans-complemented MEFs were incubated with CHIKV at 4°C for 1 h, washed extensively to
remove unbound virus, and assayed by quantitative RT-PCR (qRT-PCR). As no differences in
levels of bound CHIKV genomic RNA were detected between Ifitm3 expressing MEFs and their
corresponding controls (Fig 3.4A), we concluded that binding efficiency was not appreciably
affected. To assess whether Ifitm3 affected internalization, CHIKV was pre-bound to transcomplemented MEFs for 1 h on ice, followed by incubation at 37°C for 1 h. MEFs then were
treated with proteinase K to remove residual surface bound virus before recovery of cellular
RNA. Similar to cell surface binding assays, we observed no difference in the levels of
internalized viral RNA (Fig 3.4B). As anticipated, in control binding experiments performed at
4oC, proteinase K treatment significantly decreased (11-fold, P < 0.0001) the level of cell-bound
viral RNA (Fig 3.4C).
As we did not observe effects of Ifitm3 on attachment or internalization, we next
evaluated pH-dependent fusion. Alphaviruses can be induced to fuse at the plasma membrane in
the presence of an acidic solution (acid-bypass or fusion from without (FFWO)) (120), albeit at
low efficiency; this required us to infect at a high multiplicity of infection. To test whether
FFWO is affected by ectopic expression of Ifitm3, MEFs were pre-incubated with CHIKV at
4°C, washed to remove unbound virus, and then incubated with pre-warmed medium at pH 7.4
or pH 5.5. Subsequently, medium was replaced with normal pH culture medium supplemented
with 20 mM NH4Cl, which prevents alphavirus maturation and fusion (120), was added to inhibit
productive infection of progeny virions. Fourteen hours later, MEFs were analyzed for viral
antigen by flow cytometry. Ifitm3 trans-complemented MEFs had lower levels of CHIKV
antigen than luciferase expressing controls in WT, Ifitm3-/- and Ifitm-del MEFs (Fig 3.4D and
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E). Consistent with results with IAV (101), expression of Ifitm3 also inhibits pH-dependent
fusion of alphaviruses.
Ifitm3 inhibits alphavirus infection in vivo. To determine whether Ifitm3 has a
protective role against alphaviruses in vivo, we used an established mouse model of CHIKV
infection and arthritis (36). We inoculated 4-week old WT and Ifitm3-/- mice with CHIKV-LR in
the left footpad and measured joint swelling on days 3 and 7 after infection, which correspond to
the peaks of tissue edema and cellular infiltrates, respectively (36, 37). Whereas no difference
was seen in viral titers at these time points (Fig 3.5A), greater swelling was observed in
ipsilateral ankle joints of Ifitm3-/- compared to WT mice on both days, (Fig 3.5B and C, P <
0.001 and P < 0.01). Because of the disparity between clinical signs and virological data, we
analyzed viral burden in different tissues (serum, spleen, ankles, wrists, and quadriceps muscles)
at earlier time points (days 1 and 2 after inoculation) (Fig 3.5D-K). At day 1 after inoculation,
the serum, spleen, and ipsilateral ankle (Fig 3.5D-F) of Ifitm3-/- mice had higher viral titers
compared to WT mice (20-fold in serum P < 0.0001; 160-fold in spleen, P < 0.0001; and 2.5fold in ipsilateral ankle, P < 0.01). In comparison, at day 2, the titers in the spleen, serum and
ipsilateral ankle were similar but levels in the contralateral ankle and quadriceps muscle (Fig
3.5G and I) were somewhat higher (4.5-fold, P < 0.001; and 5-fold P < 0.01, respectively).
However, by day 3, no differences in viral titer were observed in any tissues between WT and
Ifitm3-/- mice.
The early higher viral burden in Ifitm3-/- mice corresponded to higher levels of
inflammatory chemokines and cytokines in the ipsilateral ankle (Table 3.1). The mean
concentrations of several chemokines and cytokines (e.g., IL-2, MCP-1, TNF-α, IL-1α, IL12p40, G-CSF, and GM-CSF, P < 0.05) were higher in ankles from CHIKV-infected Ifitm3-/	
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than WT mice at days 1 and/or and 2 after infection. These data suggest that in the context of
CHIKV infection in vivo, Ifitm3 contributes to restriction of early viral infection and spread,
which impacts cytokine induction and the development of clinical disease.
Given the increase in viral titers in the spleen of Ifitm3-/- mice on day 1, we hypothesized
that Ifitm3 might affect the cellular tropism of CHIKV. To identify the cell subsets that were
more susceptible to CHIKV infection, we performed flow cytometric analysis on spleens of
infected WT and Ifitm3-/- mice (Fig 3.6A-C). Splenocytes were stained for CHIKV envelope (E1
and E2) proteins using specific MAbs (37) and compared to isotype control MAbs. Inflammatory
monocytes (CD11b+Ly6G+), macrophages (CD11bhiF4/80lo), and red pulp macrophages
(CD11bloF4/80hi) expressed high levels of viral antigen (50%, 50% and 25%, respectively), with
no difference in the fraction of infected cells from WT and Ifitm3-/- cells (Fig 3.6B and data not
shown). Nonetheless, greater numbers of CHIKV antigen-positive CD11bhiF4/80lo and
CD11bloF4/80hi macrophages were detected in the spleens of Ifitm3-/- compared to WT mice (1.3
fold, P < 0.05; 1.7 fold, P < 0.05; and 2.2 fold, P < 0.05, respectively; Fig 3.6C). An increased
number of Ifitm3-/- neutrophils expressed CHIKV antigen (1.6 fold, P < 0.05), but the overall
number of neutrophils was substantially lower compared to other myeloid cell populations. No
differences in viral antigen-positive inflammatory monocytes were observed between the Ifitm3-/and WT controls, and neither Ifitm3-/- nor WT CD4+, CD8+, CD19+, or NK1.1+ cells exhibited
detectable viral protein staining (data not shown). To determine if Ifitm3-/- macrophages can
support greater replication of CHIKV, bone marrow derived macrophages were cultured from
WT and Ifitm3-/- mice, and infected at an MOI of 0.1. Viral supernatants were collected up to 72
h post infection and analyzed by focus forming assay. Ifitm3-/- macrophages produced more virus
at 24 and 48 h post infection compared to WT cells (Fig 3.6D, 12.5-fold, P < 0.01 and 10-fold, P
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< 0.01, respectively). These data suggest that a lack of Ifitm3 allows for enhanced CHIKV
infection in macrophages.
To assess whether Ifitm3 had a protective effect against other alphaviruses in vivo, we
infected 4 week-old WT and Ifitm3-/- mice with a previously described moderately pathogenic
encephalitic alphavirus strain (VEEV TC83-A3G), which is resistant to the antiviral effects of
another ISG, Ifit1 (48). Ifitm3-/- mice exhibited greater mortality (Fig 3.7A) and morbidity (as
judged by weight loss, Fig 3.7B) after VEEV TC83-A3G infection compared to WT mice.
Consistent with the clinical phenotypes, higher VEEV titers were observed at day 1 after
infection in the liver and spinal cord (3-fold, P < 0.05; 8-fold, P < 0.01, respectively, Fig 3.7C)
and day 2 after infection in the spleen, brain, and liver of Ifitm3-/- compared to WT mice (2.5fold, P < 0.05; 250-fold, P < 0.05; and 10-fold, P < 0.01, respectively, Fig 3.7C). These data
confirm that Ifitm3 restricts alphavirus infection in vivo and prevent early dissemination.
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DISCUSSION
To evaluate the potential antiviral role of Ifitm3 in restricting alphaviruses in vitro, we
infected WT, Ifitm3-/- and Ifitm-del MEFs with CHIKV, SFV, ONNV, VEEV and SINV. All
alphaviruses tested exhibited some degree of enhanced infection in Ifitm3-/- cells. In contrast,
studies with CHIKV and Ifitm2-/- MEFs showed comparable infection to WT MEFs, suggesting
that Ifitm2 is not the predominant Ifitm gene responsible for the inhibiting alphaviruses in the
context of an intact type I IFN response. The antiviral function of Ifitm3 against alphaviruses
was validated using trans-complemented MEFs that ectopically express Ifitm3. Analogous to
how IFITM3 inhibits IAV infection (78, 101), our mechanism of action studies suggest that
Ifitm3 does not affect the binding or internalization of CHIKV, but instead prevents pHdependent fusion events.
We also observed greater CHIKV infection and disease pathogenesis in vivo in animals
lacking Ifitm3 expression. Ifitm3-/- mice developed greater ankle swelling compared to WT
animals, and this difference correlated with an increased in viral burden and inflammatory
chemokine and cytokine levels at early times post inoculation. Notably, at later time points, titers
became equivalent in WT and Ifitm3-/- mice, suggesting possible immune evasion of Ifitm3 by
CHIKV, which could occur by several previously identified mechanisms including host
transcriptional shut-off (121) or antagonism of IFN signaling (122). To assess possible effects of
Ifitm3 on cellular tropism, we assessed CHIKV antigen staining using flow cytometric analysis
of splenocytes at day 1 post infection. These cells were chosen because they were easily profiled,
and exhibited substantial (160-fold) difference in viral yield at this time point. Although the
overall percentage of CHIKV-positive myeloid cells was similar in the spleens of Ifitm3-/- and
WT mice, a higher number of macrophages were positive for CHIKV antigen, suggesting a
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possible role for Ifitm3 in controlling viral growth in these cell types. One limitation of the flow
cytometry experiments is that we cannot be certain that CHIKV antigen-positive staining defines
bona fide infection, as it remains possible that we are detecting bound/opsonized virus on the
surface of cells rather than E1 and E2 proteins prior to budding. To address this issue, we tried
infection studies in WT and Ifitm3-/- mice with double subgenomic reporter gene viruses (e.g.,
CHIKV-GFP); however the fluorescence staining was too dim for conclusive results, possibly
because of the attenuation of these viruses. Nonetheless, our studies with bone marrow derived
macrophages support a role for Ifitm3 restriction of CHIKV infection in this cell type, as
increased titers were observed in cells from Ifitm3-/- mice.
Our in vivo findings were not limited to CHIKV, as we also observed greater mortality,
weight loss, and viral burden following VEEV infection of Ifitm3-/- mice. These data suggest an
important role for Ifitm3 in restricting alphavirus pathogenesis in vivo, by limiting replication
and dissemination early during infection. Future studies using analogous flow cytometric
approaches and conditional gene deletions are planned to define the cell-type specific antiviral
effect of Ifitm3 in the context of VEEV pathogenesis.
A possible antiviral role of IFITM proteins against alphaviruses has not been extensively
analyzed. Studies with pseudotyped virions (alphavirus structural proteins and retroviral RNA)
initially suggested that IFITMs had little antiviral activity against CHIKV, SINV, and VEEV (M.
Farzan, unpublished observations (52)). It remains uncertain why Ifitm3 would not inhibit
pseudotyped alphavirus virions although the icosahedral display of E1 and E2 may be altered in
these viruses, which could affect entry and fusion of virus particles. Ifitm3 has been implicated
although not definitively demonstrated as a restriction factor for alphaviruses. Karki et al
identified IFITM3 as one of 31 human ISGs that functioned synergistically with zinc finger
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antiviral protein (ZAP) to enhance restriction of SINV infection (45). Schoggins et al reported
that IFITM3 moderately reduced CHIKV and ONNV infection in human cells ectopically
expressing IFITM3 (20, 84). Consistent with these observations, a recent paper reported an
inhibitory effect of IFITM3 and IFITM1 against SFV and SINV when ectopically expressed in
human A549 cells (106). These data support our findings of an antiviral activity of Ifitm3
against multiple alphaviruses.
The characterization of Ifitm3 as an antiviral ISG against alphaviruses adds to the known
host defense genes that block alphavirus infection. ISG15 protects against SINV in vivo, likely
via conjugation (ISGylation) to viral proteins (15–17), ZAP restricts SINV, Ross River, SFV,
and VEEV by blocking the accumulation of viral genomic content in the cytoplasm (8), and
BST-2 (tetherin) prevents CHIKV egress by retaining budding virus on the plasma membrane
(19). SINV also is strongly inhibited by PKR in the context of replication in DCs (46). Finally, a
separate genetic screen revealed several unique ISGs with possible antiviral activity, against
SINV including Isg20, Ifit1, Ifit2, Ifit3, and Rsad2 (viperin) (47).
In studies with other viruses, IFITM3 appears to restrict early steps in the viral lifecycle,
particularly fusion into the cytoplasm (57, 78, 101). This is supported by data from our FFWO
experiments in the context of CHIKV infection and by recent studies with SFV (106). However,
it remains possible that IFITM3, akin to effects on HIV, could restrict alphavirus infection in a
pH insensitive manner by integrating into the viral membrane, which we are currently exploring
using mass spectrometric analysis of alphavirus virions derived from cells expressing or lacking
Ifitm3. An additional mechanism that warrants investigation is the possible role for Ifitm3 in
preventing viral budding and/or egress. IFITM3 can be detected at the plasma membrane, and its
expression and localization is enhanced upon IFN stimulation (59, 62, 119).
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In summary, we have shown that Ifitm3 can restrict several alphaviruses both in vitro and
in vivo. Our data in mice suggest that Ifitm3 may function to restrict early replication and
dissemination of alphaviruses, thereby preventing pathogenesis. Further investigation into
additional mechanisms of Ifitm3 mediated restriction of alphaviruses is warranted as well as
effects of gene polymorphisms, which could contribute to relative disease susceptibility in
humans. Indeed, a common human allelic IFITM3 variant, rs12252-C, encodes for a 21 amino
acid deletion of the N terminal part of the protein that appears to be associated with susceptibility
to IAV infection (63, 99, 100). It remains to be determined whether this or other polymorphisms
in the IFITM3 gene can be linked to more severe or persistent alphavirus infection.
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Figure 3.1

Figure 3.1. CHIKV infection is enhanced in cells lacking Ifitm3 expression.
WT, Ifitm2−/−, Ifitm3−/−, and Ifitm-del MEFs were generated from WT and gene-targeted mice.
(A) Genotyping of MEFs was performed by PCR and agarose electrophoresis. Bands
corresponding to WT and KO alleles are indicated to the right of each gel. (B) MEFs were
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pretreated with various doses of IFNβ and tested for Ifitm2 and Ifitm3 gene induction by qRTPCR. Ifitm2 expression was not detected in Ifitm2−/− and Ifitm-del MEFs, and Ifitm3 expression
was not detected in Ifitm3−/− and Ifitm-del MEFs. Bars show the means and standard errors of the
means from three independent experiments performed in duplicate. Means were compared
between control and IFNβ-treated cells using a nonparametric one-way ANOVA with Dunn's
multiple comparisons (*, P < 0.05; ***, P < 0.001; ****, P < 0.0001). (C) MEFs were pretreated
with the indicated doses of IFNβ and tested for Ifitm3 expression by quantitative Western
blotting. (Left) Means from three independent experiments were compared between control and
IFNβ-treated cells using a nonparametric one-way ANOVA with Dunn's multiple comparisons
(*, P < 0.05). (Right) A representative Western blot with loading controls (β-actin) is shown. (D
to H) The indicated MEFs were pretreated with 1 U/ml of IFNβ and subsequently infected with
CHIKV 181/25 or CHIKV-LR at an MOI of 5. (D) At 14 h postinfection, MEFs were stained for
viral E2 protein and analyzed by flow cytometry. (E and F) Cumulative flow cytometry data for
CHIKV 181/25 and CHIKV-LR. Bars show the means and standard errors of the means (SEM)
from five independent experiments performed in quadruplicate or duplicate. Means were
compared between WT and deficient cell lines using one-way ANOVA with Dunnett's multiple
comparisons (*, P < 0.05; **,P < 0.01; ***, P < 0.001; ****, P < 0.0001). (G and H) Kinetics
of CHIKV 181/25 and CHIKV-LR replication in IFNβ-pretreated WT,Ifitm3−/−, and Ifitmdel MEFs infected at an MOI of 5. Supernatant was harvested at indicated time points, and virus
titers were determined. Curves show the means and standard errors of the means from the pooled
data of two or three independent experiments performed in triplicate. Means at each time point
were compared between WT and knockout cell lines using two-way ANOVA with Dunnett's
multiple comparisons (*, P < 0.05; **,P < 0.01; ***, P < 0.001; ****, P < 0.0001).	
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Figure 3.2

Figure 3.2. Infection of other alphaviruses is enhanced in cells lacking Ifitm3 expression.
WT, Ifitm3−/−, and Ifitm-del MEFs were pretreated with the indicated concentrations of IFNβ and
subsequently infected with SFV (A), ONNV (B), VEEV-TC83 (C), or SINV (D) at an MOI of 5.
At 14 h postinfection, MEFs were stained for viral E2 proteins and analyzed by flow cytometry.
Bars represent the means and standard errors of the means from three independent experiments
performed in duplicate. For each concentration of IFNβ, means between WT and knockout cells
were compared using one-way ANOVA with Dunnett's multiple comparisons (*, P < 0.05;
**, P < 0.01; ***, P < 0.001).
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Figure 3.3	
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Figure 3.3. Ectopic expression of IFITM3 inhibits CHIKV infection. c-Myc-tagged firefly
luciferase and Ifitm3 were cloned into the pFCIV vector and introduced into WT, Ifitm3−/−,
and Ifitm-del MEFs via lentiviral transduction. (A and B) Successful transduction was
determined by staining for c-Myc tag by flow cytometry (gray-filled are negative control; black
lines, anti-c-Myc) (A) and Western blotting for firefly luciferase (detected with anti-c-Myc
antibody) and Ifitm3 (detected with anti-Ifitm3 antibody) in transcomplemented MEFs (B). βActin loading controls are provided below each gel. Results are representative of three
independent experiments. (C) Flow cytometry contour plots of CHIKV infection in
transcomplemented MEFs. Cells were infected for 6 h in the absence of IFNβ with CHIKV
181/25 at an MOI of 5. Infection was determined by flow cytometry of E2-positive cells. (D)
Pooled data from CHIKV infection. Bars represent the means and standard errors of the means
from three independent experiments done in triplicate. Means were compared by Student's t test
(**, P < 0.01).
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Figure 3.4
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Figure 3.4. Role of Ifitm3 in restricting CHIKV binding, entry, and pH-dependent fusion.
(A) CHIKV-LR was bound to firefly luciferase or Ifitm3-transcomplemented MEFs for 1 h on
ice. After repeated rinses with chilled PBS, total RNA was isolated and analyzed for CHIKV
RNA by qRT-PCR. Pooled data from 3 independent experiments done in duplicate are shown.
(B) After CHIKV-LR binding and washing, MEFs were incubated at 37°C for 1 h to allow for
virus internalization. MEFs were then treated with proteinase K on ice for 1 h to digest any
bound but not internalized virions, followed by washing, RNA extraction, and analysis by qRTPCR. Data are representative of three independent experiments performed in duplicate. (C) As a
control, we confirmed the efficiency of proteinase K for removing surface-bound (at 4°C) but not
internalized CHIKV. MEFs treated with proteinase K had lower levels of CHIKV RNA as
detected by qRT-PCR (higher threshold cycle [CT] values, P < 0.0001). (D and E) FFWO assay
of CHIKV 181/25 on transcomplemented MEFs. CHIKV (MOI of 100) was bound to cells on ice
for 2 h, followed by treatment with neutral (pH 7.4) or acidic (pH 5.5) medium at 37°C for 2 min
to induce fusion. Medium was replaced with neutral culture medium supplemented with NH4Cl
and incubated at 37°C for 14 h before analysis of CHIKV antigen-positive cells by flow
cytometry. Data represent the means and standard errors of the means from three independent
experiments done in triplicate. Means were compared by Student's t test (***, P < 0.001;
****, P < 0.0001).
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Figure 3.5
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Figure

3.5.

Ifitm3

restricts

CHIKV

pathogenesis in

vivo.

Four-week-old

WT

and Ifitm3−/− mice were inoculated with 103 FFU of CHIKV-LR in the left footpad. (A) Viral
titers in the ipsilateral ankle at days 3 and 7 postinfection. Data were pooled from two
independent experiments, and each point represents one mouse (n = 8 to 10). The dotted line
represents the limit of detection. No statistical difference was seen by the Mann-Whitney test. (B
and C) Swelling of the ipsilateral ankle of infected WT and Ifitm3−/− mice at days 3 and 7
postinfection. Area was determined by measuring the width and height of the ankle using digital
calipers. Data are pooled from two independent experiments and are normalized to the measured
area of the ankles just prior to infection. Each dot represents one mouse (n = 8 to 10). Asterisks
indicate statistical differences by the Mann-Whitney test (**, P< 0.01; ***, P < 0.001). (D to K)
Four-week-old WT and Ifitm3−/− mice were inoculated with 103 FFU of CHIKV-LR in the left
footpad. Viral burdens in the serum (D), spleen (E), ankles (F and G), muscles (H and I), and
wrists (J and K) at days 1 and 2 postinfection were determined by focus-forming assay. Dotted
lines represent the limit of detection. Data are pooled from three independent experiments, and
each dot represents one mouse (n = 13 to 16). Asterisks indicate statistical differences by the
Mann-Whitney test (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001).
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Figure 3.6
A
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Figure 3.6. Infection of splenocyte subsets by CHIKV-LR in WT and Ifitm3−/− mice.
Splenocytes from 4-week-old WT and Ifitm3−/− mice were harvested 1 day after infection
(103 FFU in the footpad); stained for neutrophils, inflammatory monocytes, dendritic cells,
eosinophils, macrophages, and red pulp macrophages and for surface expression of CHIKV E1
and E2 viral antigen; and analyzed by flow cytometry. (A) Detailed gating strategy for different
cell subsets is shown. FSC, forward scatter; SSC, side scatter. (B) Representative contour plots
of WT and Ifitm3−/− splenocytes gated for CHIKV antigen-positive cells, stained with either
isotype control or anti-CHIKV envelope protein antibody. (C) Scatter plots indicate the number
of CHIKV antigen-positive cells for each subpopulation. Data were pooled from two
independent experiments. Each dot represents one mouse (n = 9 to 10). Asterisks determine
statistical differences by the Mann-Whitney test (*, P < 0.05). Note the break in the y axis. (D)
Viral kinetics of CHIKV-LR infection in bone marrow-derived WT and Ifitm3−/− macrophages
infected at an MOI of 0.1. Data are pooled from five independent experiments performed in
triplicate, and each point indicates mean and standard error of the mean. The dotted line indicates
the limit of detection. Asterisks determine statistical differences by two-way ANOVA and
Sidak's multiple comparisons (**, P < 0.01). hpi, hours postinfection.
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Figure 3.7	
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Figure 3.7. Ifitm3 protects against VEEV pathogenesis. (A and B) Four-week-old WT
and Ifitm3−/− mice were infected with 106 FFU of VEEV-TC83-A3G in the footpad and followed
for survival (A) and morbidity by weight loss (B). Data are pooled from two independent
experiments (n = 19 to 21). Asterisks denote statistical differences by log rank test (***, P <
0.001). (C) VEEV viral burden of serum, spleen, liver, inguinal lymph nodes (iLN), popliteal
lymph nodes (pLN), brain, and spinal cord at days 1, 2, and 4 after infection of WT
and Ifitm3−/− mice. Data are pooled from four independent experiments, where each dot
represents one mouse (n = 6 to 10). Dotted lines represent the limit of detection. Asterisks
indicate statistical differences by the Mann-Whitney test (*, P < 0.05; **, P < 0.01).
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Table 3.1: Cytokine levels in joint tissue homogenates after CHIKV infection
Cytokine
IL-1α
IL-1β
IL-2
IL-3
IL-4
IL-5
IL-6
IL-9
IL-10
IL-12 (p40)
IL-12 (p70)
IL-13
IL-17
Eotaxin
G-CSF
GM-CSF
IFN-γ
KC
MCP-1
MIP-1a
MIP-1b
RANTES
TNF-α

	
  

Genotype
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3
WT
-/Ifitm3

Day +1
pg/ml
7.6 (± 1.0)
12 (± 2.4)
52 (± 11)
71 (± 14)
11 (± 1.9)
16 (± 1.8)
0.33 (± 0.06)
0.33 (± 0.06)
3.2 (± 0.2)
3.2 (± 0.5)
0.6 (± 0.2)
0.8 (± 0.4)
1.5 (± 0.4)
1.9 (± 1.0)
22 (± 7.1)
28 (± 16)
1.1 (± 0.06)
1.3 (± 0.2)
1.1 (± 0.2)
1.4 (± 0.3)
2.8 (± 0.2)
3.8 (± 0.5)
LOD (38.7)
44 (± 5.7)
0.3 (± 0.09)
0.3 (± 0.1)
151 (± 3.8)
162 (± 8.2)
0.7 (± 0.1)
0.9 (± 0.3)
43 (± 4.9)
55 (± 5.0)
LOD (1.2)
LOD (1.2)
16 (± 2.6)
23 (± 5.6)
52 (± 15)
118.5 (± 25.44)
38 (± 1.4)
50 (± 7.8)
20 (± 3.9)
34 (± 8.5)
13 (± 2.4)
12 (± 3.1)
17 (± 3.0)
41 (± 6.4)

P
0.2
0.3
0.03
0.9
0.3
0.9
0.8
0.9
0.3
0.8
0.1
0.9
0.9
0.5
0.9
0.14
>0.9
0.6
0.01
0.3
0.3
0.8
0.004

Day +2
pg/ml
9.8 (± 0.6)
14 ± 1.5)
144 (± 18)
181 (± 9.2)
15 (± 1.9)
21 (± 3.1)
0.39 (± 0.08)
0.76 (± 0.06)
4.2 (± 0.5)
6.1 (± 1.0)
3.0 (± 1.0)
3.4 (± 1.0)
8.8 (± 1.1)
11 (± 1.9)
31 (± 9.1)
107 (± 24)
3.1 (± 0.9)
5.3 (± 0.8)
10 (± 1.6)
15 (± 0.8)
6.2 (± 0.7)
7.0 (± 0.6)
LOD (38.7)
39 (± 0.8)
0.3 (± 0.08)
0.2 (± 0.06)
176 (± 11)
176 (± 12)
4.2 (± 1.2)
8.5 (± 0.8)
59 (± 6.4)
77 (± 5.7)
1.8 (± 0.3)
1.5 (± 0.14)
81 (± 15)
83 (± 13)
706 (± 119)
833 (± 70)
168 (± 29)
151 (± 13)
150 (± 33)
89 (± 23)
109 (± 28)
88 (± 24)
48 (± 7.5)
56 (± 7.4)
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P
0.03
0.2
0.09
0.006
0.1
0.7
0.4
0.006
0.02
0.02
0.5
0.9
0.8
0.9
0.007
0.04
0.7
0.8
0.4
0.8
0.2
0.8
0.5

Table 3.1. Mice were infected with 103 FFU of CHIKV-LR in the footpad. Ipsilateral joint
tissues were collected at 1 and 2 days after infection, homogenates were prepared, and the
indicated cytokines were measured by Bio-Plex array. Data represent the mean (± SEM) in pg/ml
of 9 to 11 mice per group. Statistical significance was determined by the Mann-Whitney test.
LOD indicates the limit of detection.
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Chapter 4: Conclusions and Future Directions
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CONCLUSIONS
This study attempted to identify novel antiviral ISGs using a high-throughput, gene
knockdown system in vitro. Compared to screens where candidate ISGs was expressed
ectopically, this shRNA based system would allow for the characterization of targets in the
context of a physiological antiviral state. In addition, by testing with an attenuated virus strain
and a virus not extensively studied in this context, we hoped to increase the chances of
discovering ISGs with milder, or virus family specific functions. Unfortunately, though the
initial premise of the screen was sound, the commercial shRNAs were not previously validated,
and only 1 of every 3 shRNAs against a target were guaranteed to have a significant knockdown.
In fact, for the top ranked ISGs in the screen, very few had multiple shRNAs with a Z-score
higher than the cutoff of 1.5. This suggested that the library was mostly composed of ineffective
shRNAs, or were allowing for other off-target effects and thus compromising the results of the
screen, reducing our confidence in the overall results. Independent assessment of ISGs using
CRISPR is still in progress, and generation of validated clonal lines must be done to optimize
this system.
Of the top hits, we also had access to knockout mice for four of these ISGs: Ifitm3, Ifit2,
Lamp3 and β2m. Using MEFs obtained from these mice, initial studies revealed that only Ifitm3
had a potent antiviral phenotype against alphaviruses, a family that was previously considered in
the literature to be in fact resistant to this ISG. Ifitm3 mediated restriction was not limited to the
attenuated strain CHIKV-181/25, but also reduced viral replication of the pathogenic CHIKV-LR
strain, as well as other arthritogenic and encephalitic alphaviruses in vitro. Mechanistically,
Ifitm3 did not affect CHIKV binding or entry, but restricted fusion with the plasma membrane
under conditions of ectopic expression. Ifitm3 proved to be important in vivo, as the lack of this
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ISG allowed for an increase in the early viral burden in CHIKV infected mice, an increase in foot
swelling at days 3 and 7 post infection, and an increase in the viral antigen load in splenic
macrophages. By growth curves, Ifitm3 restricts viral growth in bone marrow derived
macrophages at basal conditions, and may therefore act as a reservoir in vivo. The absence of
Ifitm3 also promoted increased mortality in mice infected with the encephalitic alphavirus
VEEV-TC83-A3G, likely due to early increased viral burden and spread.
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FUTURE DIRECTIONS
Screening for novel antiviral ISGs
Assuming that the initial shRNA screen is still worth following up on, it is necessary to
continue developing clonal CRISPR knockout lines. The bulk CRISPR lines failed due to the
genetic heterogeneity of the cells. Even partial expression of a target ISG could be sufficient to
lose a potential protective phenotype. As we observed in the Ifitm3 bulk CRISPR set, no
variation of IFN or MOI tested could show a difference in restriction compared to scrambled
negative controls, even though all the cell lines were selected for puromycin resistance. Western
blot analysis revealed that Ifitm3 protein was still being produced, especially after IFN treatment,
and was clearly sufficient to restrict CHIKV. Furthermore, validated clonal lines should be
developed in other permissive cells to confirm that any phenotypes are ISG specific, and not due
to an artifact of the cell line. A more prudent approach would be to consider restarting the screen
with a more reliable means of targeted knockdown or knockout. Whether by CRISPR, CRISPRi,
or by shRNA, the reduction of gene expression should be validated at least at the mRNA level by
qPCR. The generation of such a library will take a lot of time to properly generate, and would
ideally be done commercially or through a core service.
ISG targets should be further tested across multiple primary and stable cell lines for their
role in cell viability, basal transcription and cell cycle activity, to make sure these genes are not
essential for survival. Following this, target ISGs should be re-introduced by ectopic expression
to verify that viral restriction can be restored. Finally, relevance in vivo using knockout mouse
models and studies to determine the stages and mechanism of viral restriction can proceed.
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Characterizing Ifitm3 as an antiviral ISG
There are many questions left unanswered concerning the role of Ifitms in the context of
alphavirus pathogenesis. In our in vitro studies, we noticed that Ifitm-del locus knockout MEFs
was more susceptible against viral infection than Ifitm3-/- MEFs. This suggests that the other
Ifitms could also be involved in alphavirus restriction. While Ifitm2-/- MEFs were just as
sensitive to CHIKV as WT MEFs, the protective role of Ifitm1 and the other non-IFN stimulated
Ifitms absent in the locus deletion is currently unknown. Ifitm1-/- and Ifitm2-/- mice have recently
been backcrossed to the C57BL/6J background and are available for further in vivo studies.
C57BL/6J backcrossed Ifitm-del mice tend to die at birth, which unfortunately makes in vivo
experiments difficult. However, Ifitm-del MEFs can be used for in vitro studies. This line can be
complemented to ectopically express single Ifitms or different combinations of Ifitm genes, and
subsequently infect with CHIKV to look for differences in growth kinetics and replication.
Identification of other individual or a combination of antiviral Ifitms can be followed up by
generating and infecting new Ifitm knockout mice to determine in vivo relevance.
One of the most interesting phenotypes observed in the Ifitm3-/- mouse was the rapid
early viral titers in the spleen, ipsilateral foot and serum. This led to the finding that splenic
macrophages were more antigen positive in these mice compared to WT controls. However, we
did not study the role of Ifitm3 in stromal cells. CHIKV is known to infect muscle cells,
osteoblasts, and fibroblasts, all of which express Ifitm3. Since the titers at the joints were either
comparative or only slightly higher at all timepoints examined, we opted to not look too much
further into these tissues. To better understand the role Ifitm3 plays in restricting CHIKV
pathogenesis of stromal cells in vivo, we can take advantage of a newly established technique in
the lab called In Situ Hybridization (ISH). With this staining protocol, we can determine
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histologically how CHIKV spreads from the site of infection to the stromal and hematopoietic
cells by staining for viral RNA. Combined with H&E staining, and immunofluorescence staining
of known cells susceptible to CHIKV, ISH can help us better understand the early kinetics of
viral spread and the possible changes in viral tropism in the stromal cells of the infected ankle
joints, and may better inform us as to why we see early higher viremia and titers in the spleen of
knockout mice. As our earliest virological titers were done at 1 day post infection, these studies
should include shorter timepoints, starting at 4 hours post infection.
The role of Ifitm3 in later stages of infection is a further point of interest. For example,
CHIKV and other alphaviruses egress from host cells by budding, and may incorporate Ifitm3 as
part of their viral envelope, as has been observed with HIV-1 (72). If integration of Ifitm3 to the
alphavirus envelope can be confirmed, subsequent studies into the downstream effects of
infectivity can be considered. In particular, does the integration of Ifitm3 affect the ability of the
virion to fuse with the endosomal membrane of host cells? Does this allow for faster viral
clearance in the serum and tissues? Furthermore, it would be interesting to note if the absence of
Ifitm3 results in a greater or more sustained viral burden at late or chronic stages of infection.
As the mechanism of Ifitm3 mediated restriction is still unclear, it would be beneficial to
have an alphavirus strain that has adapted to no longer be sensitive to this ISG. Serial passages of
CHIKV either in Ifitm3-/- mice or MEFs should produce resistant variants. Genomic and
structural comparisons of Ifitm3 sensitive and insensitive strains can help us better understand
how Ifitm3 blocks endosomal viral fusion. An Ifitm3 insensitive strain may also be useful in
understanding if this ISG has any role in promoting or preventing chronic infection. In the case
of HIV-1, it has been observed that while the founder population is resistant to IFITM function,
subsequent generations become more sensitive to IFITM3 as more mutations to escape
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neutralizing antibodies are made (73, 75, 123). A similar situation can be occurring in the case of
CHIKV infection, where IFITM3 insensitive variants are responsible for maintaining a chronic
phenotype.
The IFITM3 human polymorphism rs-12252 results in a 21 amino acid deletion of the Nterminus, which prevents localization to the endosomes. While this polymorphism was initially
shown to alter sensitivity to IAV infections, subsequent studies have brought this observation
into question (80–82). Recently however, an investigation into Hantaan virus suggests that the
rs-12252 polymorphism is associated with greater disease severity and viral load (83). Thus,
further studies on the importance and relevance of IFITM3 polymorphisms in the context of
CHIKV and other viruses needs to be done. Understanding how different polymorphisms of
IFITM3 do or do not affect restriction of viruses can be insightful towards deciphering the
mechanism of this ISG.
Finally, it would be interesting to note the in vivo importance of Ifitms and in particular
Ifitm3 in the context of other alphaviruses. Our studies only looked at CHIKV pathogenesis and
only touched on VEEV pathogenesis in vivo. Further investigations into the role of Ifitm3 in vivo
against other arthritogenic and encephalitic alphaviruses will help clarify the differences in
pathogenesis and viral tropism. For example, Mayaro and Ross River are both arthritogenic
alphaviruses that induce a different swelling response compared to CHIKV (unpublished
observations, Diamond Lab). The absence of Ifitm3 can theoretically allow for amplification of
the viral kinetics and pathogenesis of these infections. It may even be possible that there are
alphaviruses that are in fact not restricted by Ifitm3 in vivo. Preliminary day 1 post infection
analysis with Mayaro suggested that there is no difference in titer in the spleen, serum or joints
(unpublished observations). The identification of natural resistant alphavirus would be beneficial
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in deciphering the mechanism of Ifitm3 restriction, and also identifying possible viral
mechanisms of bypass or escape.
As a point of interest, an investigation into the role of Ifitm3 restricting LACV infection
in vivo should be initiated. If the published in vitro data is valid and orthobunyaviruses are
restricted by Ifitm3, we can expect a survival difference in Ifitm3-/- vs WT mice. As we have
shown, Ifitm3 is protective against encephalitic alphaviruses, however the virus strain of VEEV
used is resistant to the antiviral mechanism of Ifit1. LACV however is not affected by Ifit1 (51),
theroretically making it a better pathogen to use in understanding how Ifitm3 protects the CNS.
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  an	
  shRNA	
  library	
  to	
  screen	
  for	
  antiviral	
  interferon-‐stimulated	
  genes	
  against	
  
chikungunya	
  virus	
  using	
  flow	
  cytometry.	
  
o Elucidated	
  the	
  protective	
  role	
  of	
  interferon-‐stimulated	
  gene	
  Ifitm3	
  against	
  chikungunya	
  
virus	
  in	
  both	
  cell	
  culture	
  and	
  murine	
  models	
  of	
  infection.	
  
• Characterizing	
  the	
  role	
  of	
  immune	
  cell	
  subsets	
  in	
  pregnancy	
  and	
  testicular	
  health	
  upon	
  Zika	
  virus	
  
infection.	
  	
  
	
  
National	
  Institutes	
  of	
  Health,	
  Viral	
  Pathogenesis	
  Section	
  
2007-‐2009	
  
Postbaccalaureate	
  Research	
  Fellow	
  (IRTA)	
  –	
  Ted	
  Pierson	
  Lab	
  
• Studied	
  the	
  pH	
  dependent	
  mechanisms	
  of	
  West	
  Nile	
  virus	
  entry	
  from	
  host	
  cells.	
  
o Tested	
  the	
  hypothesis	
  that	
  flavivirus	
  pH	
  dependent	
  fusion	
  is	
  directed	
  by	
  histidine	
  
residues	
  of	
  the	
  envelope	
  protein.	
  
o Generated	
  a	
  series	
  of	
  WNV	
  mutations	
  lacking	
  one	
  or	
  more	
  histidine	
  residues	
  on	
  the	
  
envelope	
  protein	
  using	
  QuikChange	
  mutagenesis.	
  
o Characterized	
  the	
  viability	
  and	
  pH	
  sensitivity	
  of	
  each	
  mutant.	
  
	
  
University	
  of	
  California	
  at	
  Berkeley,	
  Department	
  of	
  Plant	
  and	
  Microbial	
  Biology	
  	
  
2003-‐2007	
  
Undergraduate	
  Researcher	
  –	
  Krishna	
  Niyogi	
  Lab	
  
• Honors	
  Thesis:	
  Characterizing	
  the	
  genes	
  for	
  LOR3	
  and	
  NSY	
  in	
  Chlamydomonas	
  reindardtii.	
  
o Mutagenized	
  wild	
  type	
  Chlamydomonas	
  using	
  UV	
  radiation,	
  and	
  screened	
  for	
  
carotenoid	
  deficiencies	
  using	
  HPLC	
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LAB	
  RELATED	
  SKILLS	
  
	
  
Tissue	
  culture:	
   	
  
	
  
	
  
	
  
	
  
Molecular	
  biology:	
  
	
  
	
  
	
  
	
  
	
  
	
  

Growth	
  and	
  maintenance	
  of	
  primary	
  and	
  immortalized	
  cell	
  lines.	
  	
  
Experience	
  with	
  both	
  mammalian	
  and	
  insect	
  derived	
  cells.	
  

	
  

DNA	
  and	
  RNA	
  isolation	
  from	
  cell	
  lines	
  and	
  tissue.	
  	
  
	
  
	
  
	
  
PCR	
  and	
  qRT-‐PCR.	
  	
  
	
  
	
  
	
  
	
  
	
  
	
  
	
  
Mutagenesis	
  and	
  cloning	
  of	
  plasmids	
  using	
  QuikChange,	
  Gateway	
  or	
  restriction	
  
enzyme	
  digestion.	
  	
  
Transfection	
  and	
  transduction	
  of	
  cell	
  lines.	
  DNA	
  sequencing	
  and	
  analysis.	
  	
  
Knockdown	
  and	
  knockout	
  of	
  target	
  genes	
  involving	
  shRNA,	
  siRNA	
  and	
  CRISPR.	
  	
  
Gel	
  electrophoresis	
  and	
  Western	
  blots.	
  

	
  
Immunological-‐based:	
   ELISA	
  and	
  ELISPOT.	
  	
  
Flow	
  cytometry	
  of	
  cell	
  lines,	
  mouse	
  organs	
  and	
  PBMCs.	
  	
  
Production	
  and	
  maintenance	
  of	
  bone	
  marrow	
  derived	
  primary	
  macrophages.	
  	
  
Cytokine	
  assays	
  from	
  tissues	
  and	
  serum.	
  
	
  
Virology:	
  
	
  
Production	
  and	
  maintenance	
  of	
  virus.	
  	
  
Quantification	
  of	
  virus	
  using	
  qRT-‐PCR,	
  flow	
  cytometry	
  or	
  focus	
  forming	
  assay.	
  	
  
Analysis	
  of	
  viral	
  infectivity	
  via	
  growth	
  curves.	
  	
  	
  
Analysis	
  of	
  virus	
  binding,	
  entry,	
  transcription	
  and	
  egress.	
  
	
  
In	
  vivo:	
  	
  
	
  
General	
  mouse	
  handling.	
  	
  
Experience	
  in	
  ip,	
  tail	
  vein,	
  and	
  sc	
  injections.	
  	
  
Isolation	
  and	
  preparation	
  of	
  tissue	
  and	
  organ	
  samples	
  for	
  microscopy,	
  flow	
  
cytometry,	
  virological	
  analysis,	
  or	
  histology.	
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